{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "b4602f33-8691-42a1-ac38-22c99a2bc936",
   "metadata": {},
   "source": [
    "# **Fine-tuned LLM Comparison Notebook 2**\n",
    "\n",
    "This notebook compares results of the LoRA (Low Rank Adaptation) fine-tuned Flan-T5-small and the fine-tuned Flan-T5-base (fine-tuned on custom text summarisation data) to the base pretrained Flan-T5-small, Flan-T5-base, Alpaca-native and the Vicuna-13b-v1.3 LLMs\n",
    "\n",
    "Few-shots prompting is used for all LLMs in this notebook to generate summaries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "578fe30e-1779-4523-a57f-226b0c86dcee",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, warnings, torch, gc\n",
    "import pandas as pd\n",
    "from tqdm.notebook import tqdm\n",
    "from transformers import (\n",
    "    AutoTokenizer, \n",
    "    LlamaTokenizer,\n",
    "    AutoModelForCausalLM,\n",
    "    LlamaForCausalLM,\n",
    "    AutoModelForSeq2SeqLM, \n",
    "    AutoConfig,\n",
    "    pipeline\n",
    ")\n",
    "from datasets import load_dataset\n",
    "from datasets.dataset_dict import DatasetDict\n",
    "from peft import PeftConfig, PeftModel\n",
    "from rouge import Rouge\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from langchain.llms import HuggingFacePipeline\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains.summarize import load_summarize_chain\n",
    "from langchain.schema import Document\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "from typing import Dict, Iterable, Union, Any, Optional\n",
    "\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "os.environ[\"EMBEDDINGS_MODEL\"] = \"all-MiniLM-L12-v2\"\n",
    "os.environ[\"MAX_TOKENS\"] = \"2048\"\n",
    "os.environ[\"DEVICE\"] = \"cuda:0\" if torch.cuda.is_available() else \"cpu\"\n",
    "os.environ[\"DATASET_PATH\"] = \"data/doc_summary_data\"\n",
    "os.environ[\"FINETUNED_FLAN_T5_SMALL_ID\"] = \"flan-t5-small_finetuned_results\"\n",
    "os.environ[\"FINETUNED_FLAN_T5_BASE_ID\"] = \"flan-t5-base_finetuned_results\"\n",
    "os.environ[\"ALPACA_LLM\"] = \"chavinlo/alpaca-native\"\n",
    "os.environ[\"VICUNA_LLM\"] = \"lmsys/vicuna-13b-v1.3\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "81b2f672-401d-40d8-904a-0e5333b923e5",
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_on_test_data(\n",
    "    model: Union[AutoModelForSeq2SeqLM, AutoModelForCausalLM, LlamaForCausalLM], \n",
    "    tokenizer: Union[AutoTokenizer, LlamaTokenizer], \n",
    "    dataset_key: str=\"test\",\n",
    "    task=\"text2text-generation\",\n",
    "    n_docs: int = 5,\n",
    "    log_summary: bool=False,\n",
    "    log_metrics: bool=False,\n",
    "    summary_chain_kwargs: Dict[str, Any]={},\n",
    "    **kwargs):\n",
    "    \n",
    "    # switch model to eval mode\n",
    "    model.eval()\n",
    "    \n",
    "    # Define model pipeline for inference with langchain\n",
    "    kwargs = {**dict(temperature=0.1, top_p=0.15, top_k=0, repetition_penalty=1.1), **kwargs}\n",
    "\n",
    "    # define model pipeline\n",
    "    hgf_pipeline = pipeline(\n",
    "        task=task, \n",
    "        model=model, \n",
    "        tokenizer=tokenizer,\n",
    "        max_length=int(os.environ[\"MAX_TOKENS\"]),\n",
    "        **kwargs\n",
    "    )\n",
    "    llm = HuggingFacePipeline(pipeline=hgf_pipeline)\n",
    "    \n",
    "    # Define Summary chain\n",
    "    summary_chain_kwargs = {\"chain_type\": \"map_reduce\", **summary_chain_kwargs}\n",
    "    summary_chain = load_summarize_chain(llm, **summary_chain_kwargs)\n",
    "    \n",
    "    # Load dataset\n",
    "    dataset: DatasetDict = load_dataset(path=os.environ[\"DATASET_PATH\"])\n",
    "    \n",
    "    # Generate Summaries and Measure Performance (Rouge Metric and Cosine Similarity Metric)\n",
    "    rouge = Rouge()  # rouge metric object\n",
    "    embeddings_model = SentenceTransformer(os.environ[\"EMBEDDINGS_MODEL\"]) # embeddings model object\n",
    "    embeddings_model.to(os.environ[\"DEVICE\"])\n",
    "    document_ids = dataset[dataset_key][\"id\"][:n_docs]\n",
    "    documents = dataset[dataset_key][\"document\"][:n_docs]\n",
    "    target_summaries = dataset[dataset_key][\"summary\"][:n_docs]\n",
    "    _zipped = zip(document_ids, documents, target_summaries)\n",
    "    metrics_values: Iterable[Dict[str, Any]] = []\n",
    "\n",
    "    for i, (document_id, document, target_summary) in enumerate(_zipped):\n",
    "        document = Document(page_content=document)\n",
    "        try:\n",
    "            generated_summary = summary_chain.run([document])\n",
    "        except ValueError as e:\n",
    "            print(f\"Error summarizing document-{i+1}: {e}\")\n",
    "            continue\n",
    "            \n",
    "        if log_summary:\n",
    "            print(f\"DOCUMENT {document_id}: {document}\\n\")\n",
    "            print(f\"GENERATED SUMARY: {generated_summary}\\n\")\n",
    "            print(f\"TARGET SUMARY: {target_summary}\\n\")\n",
    "\n",
    "        generated_summary_embeddings, target_summary_embeddings = (\n",
    "            embeddings_model.encode(generated_summary).reshape(1, -1),\n",
    "            embeddings_model.encode(target_summary).reshape(1, -1)\n",
    "        )\n",
    "        cos_similarity = cosine_similarity(target_summary_embeddings, generated_summary_embeddings)\n",
    "        rouge_scores = rouge.get_scores(generated_summary, target_summary)\n",
    "        if log_metrics:\n",
    "            print(f\"Cosine similarity for summary {i+1}:\", cos_similarity[0][0], \"\\n\")\n",
    "            print(f\"Rouge scores for summary {i+1}:\", rouge_scores[0], \"\\n\")\n",
    "            \n",
    "        if log_metrics or log_summary:\n",
    "            print(\"-\"*120)\n",
    "            print(\"\\n\")\n",
    "        _metric = dict(semantic_similarity=cos_similarity, rouge_scores=rouge_scores)\n",
    "        metrics_values.append(_metric)\n",
    "        \n",
    "    return metrics_values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "885c01cb-8452-4b74-82a1-e32bc2307fa9",
   "metadata": {},
   "outputs": [],
   "source": [
    "INFERENCE_DATASET_KEY = \"test\"\n",
    "N_INFERENCE_DOCS = 10\n",
    "LOG_SUMMARY = True\n",
    "LOG_METRICS = True\n",
    "DELETE_LLM_AFTER_USE = True"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "53b4df71",
   "metadata": {},
   "source": [
    "## Define Few Shots Prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "3f2eecdc-1cfa-4b5d-ab26-7d68e1700b88",
   "metadata": {},
   "outputs": [],
   "source": [
    "PROMPT_TEMPLATE = \"\"\":\n",
    "\n",
    "Using the following document and summarisation pair examples below:\n",
    "\n",
    "EXAMPLES:\n",
    "\n",
    "Example 1:\n",
    "-----------------------------------\n",
    "\"document\": \"Medical Center-Lakeside, Lubbock, Texas, 79410, United States|Texas Tech University Health Sciences \\\n",
    "Center-Lubbock, Lubbock, Texas, 79430, United States|MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, \\\n",
    "77058, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States|MD\\\n",
    "Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, 77478, United States|MD Anderson Regional Care Center-The \\\n",
    "Woodlands, The Woodlands, Texas, 77384, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, \\\n",
    "American Fork, Utah, 84003, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, 84720, United States|Logan\\\n",
    "Regional Hospital, Logan, Utah, 84321, United States|Intermountain Medical Center, Murray, Utah, 84107, United \\\n",
    "States|McKay-Dee Hospital Center, Ogden, Utah, 84403, United States|Utah Valley Regional Medical Center, Provo, Utah, \\\n",
    "84604, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, 84770, United\",\n",
    "\n",
    "\"summary\": \"There are medical and cancer centers in Texas and Utah in the US.\"\n",
    "\n",
    "\n",
    "Example 2:\n",
    "-----------------------------------\n",
    "\"document\": \"Wisconsin, 54449, United States|Marshfield Medical Center, Marshfield, Wisconsin, 54449, United \\\n",
    "States|Community Memorial Hospital, Menomonee Falls, Wisconsin, 53051, United States|Aurora Cancer Care-Milwaukee, \\\n",
    "Milwaukee, Wisconsin, 53209, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, 53215, United \\\n",
    "States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Aurora Sinai Medical Center, \\\n",
    "Milwaukee, Wisconsin, 53233, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, 54548, United \\\n",
    "States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, 53149, United States|Cancer Center of Western Wisconsin, \\\n",
    "New Richmond, Wisconsin, 54017, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, 53066, \\\n",
    "United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, 54904, United States|Aurora Cancer Care-Racine, \\\n",
    "Racine, Wisconsin, 53406, United States|Marshfield Clinic at James Beck Cancer Center, Rhinelander,\",\n",
    "\n",
    "\"summary\": \"The list provides information about medical centers and cancer clinics in different cities in Wisconsin, USA.\"\n",
    "\n",
    "\n",
    "Generate a concise summary of the text below:\n",
    "\n",
    "\"{text}\"\n",
    "\n",
    "\n",
    "SUMMARY:\"\"\"\n",
    "\n",
    "PROMPT = PromptTemplate.from_template(PROMPT_TEMPLATE)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "55c1afd2-710f-4926-a577-5879c918864c",
   "metadata": {},
   "source": [
    "## Evaluate Base Pre-trained FLAN-T5-SMALL"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "2335aa06-67f5-4cbf-8162-931e3e0d82d3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (792 > 512). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1398: page_content='NCT Number: NCT03049449\\nStudy Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT03049449\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: Background:' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The study titled \"NCT Number: NCT03049449 Study Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Study URL: https://beta.clinicaltrials.gov/study/NCT03049449\"\n",
      "\n",
      "TARGET SUMARY: A study was conducted to explore the use of T cells with a specific receptor for treating lymphomas. The study has been completed, but no additional details are available.\n",
      "\n",
      "Cosine similarity for summary 1: 0.6818962 \n",
      "\n",
      "Rouge scores for summary 1: {'rouge-1': {'r': 0.17857142857142858, 'p': 0.2, 'f': 0.18867924029903896}, 'rouge-2': {'r': 0.03571428571428571, 'p': 0.04, 'f': 0.037735844072624376}, 'rouge-l': {'r': 0.17857142857142858, 'p': 0.2, 'f': 0.18867924029903896}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 2909: page_content='Interventions: DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis\\nPrimary Outcome Measures: Incidence of relapsed leukemia, Incidence of relapsed leukemia defined as \\\\> 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have \\\\< 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease., Up to 18 months\\nSecondary Outcome Measures: Incidence of acute GVHD grades II-IV and III-IV, Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \"DRUG: Ibrutinib | Other: Laboratory Biomarker Analysis - a new study on the relapsed leukemia and relapsed leukemia.\"\n",
      "\n",
      "TARGET SUMARY: This study assesses the effectiveness of Ibrutinib in preventing relapsed leukemia after allogeneic hematopoietic cell transplantation. The primary outcome measure is the occurrence of relapsed leukemia, while secondary measures include the incidence of acute graft-versus-host disease.\n",
      "\n",
      "Cosine similarity for summary 2: 0.79964554 \n",
      "\n",
      "Rouge scores for summary 2: {'rouge-1': {'r': 0.16129032258064516, 'p': 0.29411764705882354, 'f': 0.20833332875868066}, 'rouge-2': {'r': 0.02857142857142857, 'p': 0.058823529411764705, 'f': 0.03846153406065139}, 'rouge-l': {'r': 0.12903225806451613, 'p': 0.23529411764705882, 'f': 0.166666662092014}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 4698: page_content='54476, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The United States is the location of the Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, 54494, United States, which is located in Cheyenne, Wyoming, 82001, United States, which is the location of the Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82414, United States, which is the location of the Billings Clinic-Cody, Cody, Wyoming, 82851, United States.\n",
      "\n",
      "TARGET SUMARY: This summary provides a list of medical centers in various cities in the United States, including Wisconsin Rapids, Wisconsin, and several cities in Wyoming. The medical centers mentioned include cancer centers and general medical facilities.\n",
      "\n",
      "Cosine similarity for summary 3: 0.5755552 \n",
      "\n",
      "Rouge scores for summary 3: {'rouge-1': {'r': 0.3333333333333333, 'p': 0.2903225806451613, 'f': 0.31034482260998814}, 'rouge-2': {'r': 0.09375, 'p': 0.07692307692307693, 'f': 0.08450703730212289}, 'rouge-l': {'r': 0.25925925925925924, 'p': 0.22580645161290322, 'f': 0.2413793053686089}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (2279 > 1024). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1949: page_content=\"Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87106, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, 87109, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, 88011, United States|Women's Cancer Care Associates LLC, Albany, New York, 12208, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|State University of New York Downstate Medical Center, Brooklyn, New York, 11203, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, 11215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|New York Hospital Medical Center of Queens, Fresh Meadows, New York, 11365, United States|Memorial Sloan Kettering\" metadata={}\n",
      "\n",
      "GENERATED SUMARY: The Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States | University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States | Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87102, United States | Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87102, United States | Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87102, United States | Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87102, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215, United States | Rose Park Cancer Institute, Buffalo, New York, 11215,\n",
      "\n",
      "TARGET SUMARY: The summary provides a list of cancer centers and medical facilities in different US cities, such as New Jersey, New Mexico, and New York.\n",
      "\n",
      "Cosine similarity for summary 4: 0.6952962 \n",
      "\n",
      "Rouge scores for summary 4: {'rouge-1': {'r': 0.23809523809523808, 'p': 0.16666666666666666, 'f': 0.19607842652825846}, 'rouge-2': {'r': 0.08695652173913043, 'p': 0.05405405405405406, 'f': 0.06666666193888922}, 'rouge-l': {'r': 0.19047619047619047, 'p': 0.13333333333333333, 'f': 0.15686274025374872}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1354: page_content='Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\\nStudy Results: NO\\nConditions: Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia\\nInterventions: DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Etoposide\\nPrimary Outcome Measures: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors, 30 Days post treatment initiation' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The list of medical centers and cancer clinics in Wisconsin, USA, is incomplete.\n",
      "\n",
      "TARGET SUMARY: This research is studying the use of Carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors. The goal is to determine the maximum tolerated dose and any toxicities associated with this treatment. The primary focus is on assessing the safety and tolerability of the combination therapy.\n",
      "\n",
      "Cosine similarity for summary 5: 0.12333609 \n",
      "\n",
      "Rouge scores for summary 5: {'rouge-1': {'r': 0.1282051282051282, 'p': 0.38461538461538464, 'f': 0.19230768855769237}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.10256410256410256, 'p': 0.3076923076923077, 'f': 0.15384615009615396}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3405: page_content='Other Outcome Measures: unknown\\nSponsor: Emory University\\nCollaborators: Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny|National Cancer Institute (NCI)|National Institutes of Health (NIH)\\nSex: ALL\\nAge: ADULT, OLDER_ADULT\\nPhases: PHASE1\\nEnrollment: 23\\nFunder Type: OTHER\\nStudy Type: INTERVENTIONAL\\nStudy Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\nOther IDs: IRB00104234|NCI-2018-01217|Winship4398-18|P30CA138292\\nStart Date: 2018-10-24\\nPrimary Completion Date: 2024-05-05\\nCompletion Date: 2024-05-05\\nFirst Posted: 2018-07-30\\nResults First Posted: unknown\\nLast Update Posted: 2023-05-31\\nLocations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States\\nStudy Documents: Informed Consent Form' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The United States Study Documents: Informed Consent Form\n",
      "\n",
      "TARGET SUMARY: This study, sponsored by Emory University and in collaboration with other organizations, is evaluating an intervention for adult and older adult patients with an unknown outcome measure. It is in Phase 1 and has enrolled 23 participants. The study is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The primary purpose is treatment. The study began on October 24, 2018, and is expected to be completed on May 5, 2024. The study is taking place at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah. The study includes an informed consent form.\n",
      "\n",
      "Cosine similarity for summary 6: 0.16365147 \n",
      "\n",
      "Rouge scores for summary 6: {'rouge-1': {'r': 0.013333333333333334, 'p': 0.125, 'f': 0.024096383800261415}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.013333333333333334, 'p': 0.125, 'f': 0.024096383800261415}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1955: page_content='57701, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, 78745, United States|Texas Oncology Bedford, Bedford, Texas, 76022, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann Texas Medical Center, Houston, Texas, 77030, United States|West Texas Cancer Center, Odessa, Texas, 79761, United States|Houston Methodist' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The United States is home to the largest cancer center in the world, the University of Texas Medical Branch, Galveston, Texas, 77030, and the West Texas Cancer Center, Odessa, Texas, 79761.\n",
      "\n",
      "TARGET SUMARY: The list provides cancer treatment centers and hospitals in different cities in Texas, USA.\n",
      "\n",
      "Cosine similarity for summary 7: 0.6754292 \n",
      "\n",
      "Rouge scores for summary 7: {'rouge-1': {'r': 0.38461538461538464, 'p': 0.19230769230769232, 'f': 0.256410251965812}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.3076923076923077, 'p': 0.15384615384615385, 'f': 0.2051282006837608}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (1658 > 1024). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 3655: page_content='* Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.\\n* Partial response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The list includes the following: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes: \"The list includes:\n",
      "\n",
      "TARGET SUMARY: A complete response in cancer treatment refers to the disappearance of all target lesions, decrease in lymph node size, disappearance of non-target lesions, and return of tumor marker levels to normal. A partial response is when there is at least a 30% decrease in the size of target lesions.\n",
      "\n",
      "Cosine similarity for summary 8: 0.08782922 \n",
      "\n",
      "Rouge scores for summary 8: {'rouge-1': {'r': 0.02857142857142857, 'p': 0.14285714285714285, 'f': 0.04761904484127}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.02857142857142857, 'p': 0.14285714285714285, 'f': 0.04761904484127}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1636: page_content='NCT Number: NCT02785939\\nStudy Title: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT02785939\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.\\nStudy Results: YES\\nConditions: CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \"Palbociclib is a second-line therapy in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment,\" says the American Cancer Center.\n",
      "\n",
      "TARGET SUMARY: The study evaluated the effectiveness of palbociclib in treating patients with recurrent stage IV squamous cell lung cancer. Positive results were found, suggesting that palbociclib may slow down cell cycle progression and shrink tumors. The study focused on patients with cell cycle gene alterations.\n",
      "\n",
      "Cosine similarity for summary 9: 0.89718556 \n",
      "\n",
      "Rouge scores for summary 9: {'rouge-1': {'r': 0.3888888888888889, 'p': 0.45161290322580644, 'f': 0.4179104427890399}, 'rouge-2': {'r': 0.225, 'p': 0.2903225806451613, 'f': 0.25352112184090464}, 'rouge-l': {'r': 0.3333333333333333, 'p': 0.3870967741935484, 'f': 0.35820895025172644}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 330: page_content='10 months|Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)|Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)' metadata={}\n",
      "\n",
      "GENERATED SUMARY: A new study reveals that SX-682 is a single agent and in combination with plasma and serum samples.\n",
      "\n",
      "TARGET SUMARY: This study will analyze the effects of SX-682 alone and in combination with M7824 by collecting and analyzing plasma and serum samples to measure drug concentration and detect the presence of M7824.\n",
      "\n",
      "Cosine similarity for summary 10: 0.7896017 \n",
      "\n",
      "Rouge scores for summary 10: {'rouge-1': {'r': 0.34615384615384615, 'p': 0.5294117647058824, 'f': 0.41860464638182804}, 'rouge-2': {'r': 0.1935483870967742, 'p': 0.35294117647058826, 'f': 0.2499999954253473}, 'rouge-l': {'r': 0.34615384615384615, 'p': 0.5294117647058824, 'f': 0.41860464638182804}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Load peft config for pre-trained checkpoint etc. \n",
    "flan_t5_small_config = PeftConfig.from_pretrained(os.environ[\"FINETUNED_FLAN_T5_SMALL_ID\"])\n",
    "\n",
    "# load base LLM model and tokenizer\n",
    "flan_t5_small_model = AutoModelForSeq2SeqLM.from_pretrained(\n",
    "    flan_t5_small_config.base_model_name_or_path,  \n",
    "    load_in_8bit=True,  \n",
    "    device_map=\"auto\",\n",
    ")\n",
    "flan_t5_small_tokenizer = AutoTokenizer.from_pretrained(\n",
    "    flan_t5_small_config.base_model_name_or_path, \n",
    ")\n",
    "\n",
    "flan_t5_small_performance = run_on_test_data(\n",
    "    flan_t5_small_model, \n",
    "    flan_t5_small_tokenizer, \n",
    "    INFERENCE_DATASET_KEY, \n",
    "    task=\"text2text-generation\", \n",
    "    n_docs=N_INFERENCE_DOCS,\n",
    "    log_summary=LOG_SUMMARY,\n",
    "    log_metrics=LOG_METRICS,\n",
    "    summary_chain_kwargs={\"combine_prompt\": PROMPT},\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c5c520d3-0251-48d7-8ef0-63827e017dfc",
   "metadata": {},
   "source": [
    "## Evaluate LoRA Fine-tuned FLAN-T5-SMALL"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "c2b42b7c-c5f3-41e0-b00d-c5a65c90a773",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The model 'PeftModelForSeq2SeqLM' is not supported for text2text-generation. Supported models are ['BartForConditionalGeneration', 'BigBirdPegasusForConditionalGeneration', 'BlenderbotForConditionalGeneration', 'BlenderbotSmallForConditionalGeneration', 'EncoderDecoderModel', 'FSMTForConditionalGeneration', 'GPTSanJapaneseForConditionalGeneration', 'LEDForConditionalGeneration', 'LongT5ForConditionalGeneration', 'M2M100ForConditionalGeneration', 'MarianMTModel', 'MBartForConditionalGeneration', 'MT5ForConditionalGeneration', 'MvpForConditionalGeneration', 'NllbMoeForConditionalGeneration', 'PegasusForConditionalGeneration', 'PegasusXForConditionalGeneration', 'PLBartForConditionalGeneration', 'ProphetNetForConditionalGeneration', 'SwitchTransformersForConditionalGeneration', 'T5ForConditionalGeneration', 'UMT5ForConditionalGeneration', 'XLMProphetNetForConditionalGeneration'].\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1398: page_content='NCT Number: NCT03049449\\nStudy Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT03049449\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: Background:' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical centers and cancer clinics in different cities in Wisconsin, USA.\n",
      "\n",
      "TARGET SUMARY: A study was conducted to explore the use of T cells with a specific receptor for treating lymphomas. The study has been completed, but no additional details are available.\n",
      "\n",
      "Cosine similarity for summary 1: 0.20355211 \n",
      "\n",
      "Rouge scores for summary 1: {'rouge-1': {'r': 0.10714285714285714, 'p': 0.1875, 'f': 0.13636363173553734}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.07142857142857142, 'p': 0.125, 'f': 0.09090908628099197}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 2909: page_content='Interventions: DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis\\nPrimary Outcome Measures: Incidence of relapsed leukemia, Incidence of relapsed leukemia defined as \\\\> 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have \\\\< 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease., Up to 18 months\\nSecondary Outcome Measures: Incidence of acute GVHD grades II-IV and III-IV, Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: This study aims to evaluate the effectiveness of Ibrutinib and laboratory biomarker analysis in treating relapsed leukemia, including relapsed leukemia if they receive active treatment for progressive leukemia after allogeneic HCT. The study will assess the incidence of acute GVHD grades II-IV and III-IV and assess the secondary outcome.\n",
      "\n",
      "TARGET SUMARY: This study assesses the effectiveness of Ibrutinib in preventing relapsed leukemia after allogeneic hematopoietic cell transplantation. The primary outcome measure is the occurrence of relapsed leukemia, while secondary measures include the incidence of acute graft-versus-host disease.\n",
      "\n",
      "Cosine similarity for summary 2: 0.7946706 \n",
      "\n",
      "Rouge scores for summary 2: {'rouge-1': {'r': 0.5483870967741935, 'p': 0.425, 'f': 0.4788732345169609}, 'rouge-2': {'r': 0.3142857142857143, 'p': 0.23404255319148937, 'f': 0.26829267803390844}, 'rouge-l': {'r': 0.4838709677419355, 'p': 0.375, 'f': 0.4225352063479469}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 4698: page_content='54476, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical centers and cancer clinics in different states in the US, including Wisconsin and Wyoming.\n",
      "\n",
      "TARGET SUMARY: This summary provides a list of medical centers in various cities in the United States, including Wisconsin Rapids, Wisconsin, and several cities in Wyoming. The medical centers mentioned include cancer centers and general medical facilities.\n",
      "\n",
      "Cosine similarity for summary 3: 0.8297062 \n",
      "\n",
      "Rouge scores for summary 3: {'rouge-1': {'r': 0.5555555555555556, 'p': 0.7894736842105263, 'f': 0.6521739081947071}, 'rouge-2': {'r': 0.28125, 'p': 0.45, 'f': 0.3461538414201184}, 'rouge-l': {'r': 0.5555555555555556, 'p': 0.7894736842105263, 'f': 0.6521739081947071}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1949: page_content=\"Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87106, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, 87109, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, 88011, United States|Women's Cancer Care Associates LLC, Albany, New York, 12208, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|State University of New York Downstate Medical Center, Brooklyn, New York, 11203, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, 11215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|New York Hospital Medical Center of Queens, Fresh Meadows, New York, 11365, United States|Memorial Sloan Kettering\" metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical centers and hospitals in different states in the US, including New Jersey and New York.\n",
      "\n",
      "TARGET SUMARY: The summary provides a list of cancer centers and medical facilities in different US cities, such as New Jersey, New Mexico, and New York.\n",
      "\n",
      "Cosine similarity for summary 4: 0.8062612 \n",
      "\n",
      "Rouge scores for summary 4: {'rouge-1': {'r': 0.6190476190476191, 'p': 0.6842105263157895, 'f': 0.6499999950125002}, 'rouge-2': {'r': 0.391304347826087, 'p': 0.42857142857142855, 'f': 0.4090909041012397}, 'rouge-l': {'r': 0.5714285714285714, 'p': 0.631578947368421, 'f': 0.5999999950125001}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1354: page_content='Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\\nStudy Results: NO\\nConditions: Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia\\nInterventions: DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Etoposide\\nPrimary Outcome Measures: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors, 30 Days post treatment initiation' metadata={}\n",
      "\n",
      "GENERATED SUMARY: This study is investigating the effectiveness of carfilzomib in treating multiple myeloma, focusing on pediatric patients with relapsed/refractory leukemias and solid tumors. The main focus is on pediatric patients with relapsed/refractory leukemias and solid tumors.\n",
      "\n",
      "TARGET SUMARY: This research is studying the use of Carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors. The goal is to determine the maximum tolerated dose and any toxicities associated with this treatment. The primary focus is on assessing the safety and tolerability of the combination therapy.\n",
      "\n",
      "Cosine similarity for summary 5: 0.76078916 \n",
      "\n",
      "Rouge scores for summary 5: {'rouge-1': {'r': 0.41025641025641024, 'p': 0.64, 'f': 0.49999999523925787}, 'rouge-2': {'r': 0.19230769230769232, 'p': 0.38461538461538464, 'f': 0.256410251965812}, 'rouge-l': {'r': 0.41025641025641024, 'p': 0.64, 'f': 0.49999999523925787}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3405: page_content='Other Outcome Measures: unknown\\nSponsor: Emory University\\nCollaborators: Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny|National Cancer Institute (NCI)|National Institutes of Health (NIH)\\nSex: ALL\\nAge: ADULT, OLDER_ADULT\\nPhases: PHASE1\\nEnrollment: 23\\nFunder Type: OTHER\\nStudy Type: INTERVENTIONAL\\nStudy Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\nOther IDs: IRB00104234|NCI-2018-01217|Winship4398-18|P30CA138292\\nStart Date: 2018-10-24\\nPrimary Completion Date: 2024-05-05\\nCompletion Date: 2024-05-05\\nFirst Posted: 2018-07-30\\nResults First Posted: unknown\\nLast Update Posted: 2023-05-31\\nLocations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States\\nStudy Documents: Informed Consent Form' metadata={}\n",
      "\n",
      "GENERATED SUMARY: This study is a phase 1 trial aimed at treating adults and older adults with an unknown outcome measure. It is a phase 1 trial with no masking. The results were first posted on May 31, 2023, with the last update on May 31, 2023.\n",
      "\n",
      "TARGET SUMARY: This study, sponsored by Emory University and in collaboration with other organizations, is evaluating an intervention for adult and older adult patients with an unknown outcome measure. It is in Phase 1 and has enrolled 23 participants. The study is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The primary purpose is treatment. The study began on October 24, 2018, and is expected to be completed on May 5, 2024. The study is taking place at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah. The study includes an informed consent form.\n",
      "\n",
      "Cosine similarity for summary 6: 0.57289493 \n",
      "\n",
      "Rouge scores for summary 6: {'rouge-1': {'r': 0.22666666666666666, 'p': 0.5, 'f': 0.3119266012120192}, 'rouge-2': {'r': 0.08571428571428572, 'p': 0.23684210526315788, 'f': 0.12587412197173467}, 'rouge-l': {'r': 0.22666666666666666, 'p': 0.5, 'f': 0.3119266012120192}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1955: page_content='57701, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, 78745, United States|Texas Oncology Bedford, Bedford, Texas, 76022, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann Texas Medical Center, Houston, Texas, 77030, United States|West Texas Cancer Center, Odessa, Texas, 79761, United States|Houston Methodist' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical and cancer centers in different cities in the US, including Texas, Utah, and Wisconsin.\n",
      "\n",
      "TARGET SUMARY: The list provides cancer treatment centers and hospitals in different cities in Texas, USA.\n",
      "\n",
      "Cosine similarity for summary 7: 0.8291368 \n",
      "\n",
      "Rouge scores for summary 7: {'rouge-1': {'r': 0.7692307692307693, 'p': 0.5263157894736842, 'f': 0.6249999951757813}, 'rouge-2': {'r': 0.23076923076923078, 'p': 0.15, 'f': 0.181818177043159}, 'rouge-l': {'r': 0.6153846153846154, 'p': 0.42105263157894735, 'f': 0.4999999951757813}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3655: page_content='* Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.\\n* Partial response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical centers and cancer clinics in different cities in Wisconsin, USA.\n",
      "\n",
      "TARGET SUMARY: A complete response in cancer treatment refers to the disappearance of all target lesions, decrease in lymph node size, disappearance of non-target lesions, and return of tumor marker levels to normal. A partial response is when there is at least a 30% decrease in the size of target lesions.\n",
      "\n",
      "Cosine similarity for summary 8: 0.2755678 \n",
      "\n",
      "Rouge scores for summary 8: {'rouge-1': {'r': 0.14285714285714285, 'p': 0.3125, 'f': 0.19607842706651296}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.08571428571428572, 'p': 0.1875, 'f': 0.11764705451749341}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1636: page_content='NCT Number: NCT02785939\\nStudy Title: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT02785939\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.\\nStudy Results: YES\\nConditions: CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The phase II/III trial examined the effectiveness of palbociclib in treating cell cycle gene alteration positive patients with recurrent stage IV squamous cell lung cancer that has returned after treatment. The study included all screened patients positive for cell cycle gene modifications that slow cell cycle progression and shrink tumors.\n",
      "\n",
      "TARGET SUMARY: The study evaluated the effectiveness of palbociclib in treating patients with recurrent stage IV squamous cell lung cancer. Positive results were found, suggesting that palbociclib may slow down cell cycle progression and shrink tumors. The study focused on patients with cell cycle gene alterations.\n",
      "\n",
      "Cosine similarity for summary 9: 0.93770206 \n",
      "\n",
      "Rouge scores for summary 9: {'rouge-1': {'r': 0.6944444444444444, 'p': 0.625, 'f': 0.6578947318559558}, 'rouge-2': {'r': 0.5, 'p': 0.43478260869565216, 'f': 0.465116274094105}, 'rouge-l': {'r': 0.6944444444444444, 'p': 0.625, 'f': 0.6578947318559558}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 330: page_content='10 months|Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)|Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The study examined the effects of SX-682 on patients' health using various medical centers and cancer clinics in different cities in the United States.\n",
      "\n",
      "TARGET SUMARY: This study will analyze the effects of SX-682 alone and in combination with M7824 by collecting and analyzing plasma and serum samples to measure drug concentration and detect the presence of M7824.\n",
      "\n",
      "Cosine similarity for summary 10: 0.73237205 \n",
      "\n",
      "Rouge scores for summary 10: {'rouge-1': {'r': 0.2692307692307692, 'p': 0.3181818181818182, 'f': 0.29166666170138894}, 'rouge-2': {'r': 0.0967741935483871, 'p': 0.13043478260869565, 'f': 0.1111111062208507}, 'rouge-l': {'r': 0.2692307692307692, 'p': 0.3181818181818182, 'f': 0.29166666170138894}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# load peft flan-t5-small\n",
    "flan_t5_small_model = PeftModel.from_pretrained(\n",
    "    flan_t5_small_model, \n",
    "    os.environ[\"FINETUNED_FLAN_T5_SMALL_ID\"],\n",
    "    device_map=\"auto\"\n",
    ")\n",
    "\n",
    "lora_flan_t5_small_performance = run_on_test_data(\n",
    "    flan_t5_small_model, \n",
    "    flan_t5_small_tokenizer, \n",
    "    INFERENCE_DATASET_KEY, \n",
    "    task=\"text2text-generation\", \n",
    "    n_docs=N_INFERENCE_DOCS,\n",
    "    log_summary=LOG_SUMMARY,\n",
    "    log_metrics=LOG_METRICS,\n",
    "    summary_chain_kwargs={\"combine_prompt\": PROMPT},\n",
    ")\n",
    "\n",
    "if DELETE_LLM_AFTER_USE:\n",
    "    #model.to(torch.device(\"cpu\"))\n",
    "    del flan_t5_small_model, flan_t5_small_tokenizer\n",
    "    gc.collect()\n",
    "    torch.cuda.empty_cache()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1e02a88c-df0b-4e84-a2c0-774db631d030",
   "metadata": {},
   "source": [
    "## Evaluate Base Pretrained FLAN-T5-BASE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "3cbb01ae-fa2a-4745-a0d3-09ffac433d6f",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of T5ForConditionalGeneration were not initialized from the model checkpoint at google/flan-t5-base and are newly initialized: ['encoder.embed_tokens.weight', 'decoder.embed_tokens.weight']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n",
      "Token indices sequence length is longer than the specified maximum sequence length for this model (745 > 512). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1398: page_content='NCT Number: NCT03049449\\nStudy Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT03049449\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: Background:' metadata={}\n",
      "\n",
      "GENERATED SUMARY: A new antigen receptor can be used to treat cancer.\n",
      "\n",
      "TARGET SUMARY: A study was conducted to explore the use of T cells with a specific receptor for treating lymphomas. The study has been completed, but no additional details are available.\n",
      "\n",
      "Cosine similarity for summary 1: 0.5890186 \n",
      "\n",
      "Rouge scores for summary 1: {'rouge-1': {'r': 0.10714285714285714, 'p': 0.3, 'f': 0.157894732963989}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.07142857142857142, 'p': 0.2, 'f': 0.10526315401662063}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 2909: page_content='Interventions: DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis\\nPrimary Outcome Measures: Incidence of relapsed leukemia, Incidence of relapsed leukemia defined as \\\\> 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have \\\\< 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease., Up to 18 months\\nSecondary Outcome Measures: Incidence of acute GVHD grades II-IV and III-IV, Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The National Institutes of Health is to conduct a clinical trial of Ibrutinib in patients with advanced leukemia.\n",
      "\n",
      "TARGET SUMARY: This study assesses the effectiveness of Ibrutinib in preventing relapsed leukemia after allogeneic hematopoietic cell transplantation. The primary outcome measure is the occurrence of relapsed leukemia, while secondary measures include the incidence of acute graft-versus-host disease.\n",
      "\n",
      "Cosine similarity for summary 2: 0.7751866 \n",
      "\n",
      "Rouge scores for summary 2: {'rouge-1': {'r': 0.1935483870967742, 'p': 0.35294117647058826, 'f': 0.2499999954253473}, 'rouge-2': {'r': 0.05714285714285714, 'p': 0.11764705882352941, 'f': 0.0769230725221896}, 'rouge-l': {'r': 0.16129032258064516, 'p': 0.29411764705882354, 'f': 0.20833332875868066}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 4698: page_content='54476, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The United States has a number of cancer centers in the Midwest, including the Aspirus UW Cancer Center in Wisconsin Rapids, Wisconsin, and the Marshfield Clinic in Wisconsin Rapids, Wisconsin.\n",
      "\n",
      "TARGET SUMARY: This summary provides a list of medical centers in various cities in the United States, including Wisconsin Rapids, Wisconsin, and several cities in Wyoming. The medical centers mentioned include cancer centers and general medical facilities.\n",
      "\n",
      "Cosine similarity for summary 3: 0.57993495 \n",
      "\n",
      "Rouge scores for summary 3: {'rouge-1': {'r': 0.48148148148148145, 'p': 0.5652173913043478, 'f': 0.519999995032}, 'rouge-2': {'r': 0.1875, 'p': 0.2222222222222222, 'f': 0.20338982554438392}, 'rouge-l': {'r': 0.4444444444444444, 'p': 0.5217391304347826, 'f': 0.47999999503199997}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1949: page_content=\"Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87106, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, 87109, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, 88011, United States|Women's Cancer Care Associates LLC, Albany, New York, 12208, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|State University of New York Downstate Medical Center, Brooklyn, New York, 11203, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, 11215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|New York Hospital Medical Center of Queens, Fresh Meadows, New York, 11365, United States|Memorial Sloan Kettering\" metadata={}\n",
      "\n",
      "GENERATED SUMARY: The National Cancer Institute has announced it will donate $500,000 to the Center for Clinical Oncology in Albuquerque, New Mexico.\n",
      "\n",
      "TARGET SUMARY: The summary provides a list of cancer centers and medical facilities in different US cities, such as New Jersey, New Mexico, and New York.\n",
      "\n",
      "Cosine similarity for summary 4: 0.50035274 \n",
      "\n",
      "Rouge scores for summary 4: {'rouge-1': {'r': 0.14285714285714285, 'p': 0.15, 'f': 0.14634145841760873}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.14285714285714285, 'p': 0.15, 'f': 0.14634145841760873}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1354: page_content='Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\\nStudy Results: NO\\nConditions: Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia\\nInterventions: DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Etoposide\\nPrimary Outcome Measures: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors, 30 Days post treatment initiation' metadata={}\n",
      "\n",
      "GENERATED SUMARY: Carfilzomib is approved for adults with multiple myeloma.\n",
      "\n",
      "TARGET SUMARY: This research is studying the use of Carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors. The goal is to determine the maximum tolerated dose and any toxicities associated with this treatment. The primary focus is on assessing the safety and tolerability of the combination therapy.\n",
      "\n",
      "Cosine similarity for summary 5: 0.6413926 \n",
      "\n",
      "Rouge scores for summary 5: {'rouge-1': {'r': 0.07692307692307693, 'p': 0.375, 'f': 0.12765957164327757}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.07692307692307693, 'p': 0.375, 'f': 0.12765957164327757}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3405: page_content='Other Outcome Measures: unknown\\nSponsor: Emory University\\nCollaborators: Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny|National Cancer Institute (NCI)|National Institutes of Health (NIH)\\nSex: ALL\\nAge: ADULT, OLDER_ADULT\\nPhases: PHASE1\\nEnrollment: 23\\nFunder Type: OTHER\\nStudy Type: INTERVENTIONAL\\nStudy Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\nOther IDs: IRB00104234|NCI-2018-01217|Winship4398-18|P30CA138292\\nStart Date: 2018-10-24\\nPrimary Completion Date: 2024-05-05\\nCompletion Date: 2024-05-05\\nFirst Posted: 2018-07-30\\nResults First Posted: unknown\\nLast Update Posted: 2023-05-31\\nLocations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States\\nStudy Documents: Informed Consent Form' metadata={}\n",
      "\n",
      "GENERATED SUMARY: A cancer center in Wisconsin will donate $2 million to a study to find out how to treat it.\n",
      "\n",
      "TARGET SUMARY: This study, sponsored by Emory University and in collaboration with other organizations, is evaluating an intervention for adult and older adult patients with an unknown outcome measure. It is in Phase 1 and has enrolled 23 participants. The study is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The primary purpose is treatment. The study began on October 24, 2018, and is expected to be completed on May 5, 2024. The study is taking place at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah. The study includes an informed consent form.\n",
      "\n",
      "Cosine similarity for summary 6: 0.3615845 \n",
      "\n",
      "Rouge scores for summary 6: {'rouge-1': {'r': 0.05333333333333334, 'p': 0.23529411764705882, 'f': 0.08695651872637063}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.05333333333333334, 'p': 0.23529411764705882, 'f': 0.08695651872637063}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1955: page_content='57701, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, 78745, United States|Texas Oncology Bedford, Bedford, Texas, 76022, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann Texas Medical Center, Houston, Texas, 77030, United States|West Texas Cancer Center, Odessa, Texas, 79761, United States|Houston Methodist' metadata={}\n",
      "\n",
      "GENERATED SUMARY: Texas Oncology is a cancer center in Fort Worth, Texas.\n",
      "\n",
      "TARGET SUMARY: The list provides cancer treatment centers and hospitals in different cities in Texas, USA.\n",
      "\n",
      "Cosine similarity for summary 7: 0.7162998 \n",
      "\n",
      "Rouge scores for summary 7: {'rouge-1': {'r': 0.15384615384615385, 'p': 0.2222222222222222, 'f': 0.18181817698347122}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.15384615384615385, 'p': 0.2222222222222222, 'f': 0.18181817698347122}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3655: page_content='* Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.\\n* Partial response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The most common symptoms of a lymph node biopsy are:\n",
      "\n",
      "TARGET SUMARY: A complete response in cancer treatment refers to the disappearance of all target lesions, decrease in lymph node size, disappearance of non-target lesions, and return of tumor marker levels to normal. A partial response is when there is at least a 30% decrease in the size of target lesions.\n",
      "\n",
      "Cosine similarity for summary 8: 0.28742784 \n",
      "\n",
      "Rouge scores for summary 8: {'rouge-1': {'r': 0.11428571428571428, 'p': 0.4, 'f': 0.17777777432098768}, 'rouge-2': {'r': 0.021739130434782608, 'p': 0.1111111111111111, 'f': 0.03636363362644649}, 'rouge-l': {'r': 0.08571428571428572, 'p': 0.3, 'f': 0.1333333298765433}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1636: page_content='NCT Number: NCT02785939\\nStudy Title: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT02785939\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.\\nStudy Results: YES\\nConditions: CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7' metadata={}\n",
      "\n",
      "GENERATED SUMARY: A new treatment for recurrent squamous cell lung cancer.\n",
      "\n",
      "TARGET SUMARY: The study evaluated the effectiveness of palbociclib in treating patients with recurrent stage IV squamous cell lung cancer. Positive results were found, suggesting that palbociclib may slow down cell cycle progression and shrink tumors. The study focused on patients with cell cycle gene alterations.\n",
      "\n",
      "Cosine similarity for summary 9: 0.69015 \n",
      "\n",
      "Rouge scores for summary 9: {'rouge-1': {'r': 0.1388888888888889, 'p': 0.5555555555555556, 'f': 0.22222221902222228}, 'rouge-2': {'r': 0.075, 'p': 0.375, 'f': 0.12499999722222227}, 'rouge-l': {'r': 0.1388888888888889, 'p': 0.5555555555555556, 'f': 0.22222221902222228}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 330: page_content='10 months|Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)|Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)' metadata={}\n",
      "\n",
      "GENERATED SUMARY: SX-682 as a single agent and in combination will be analyzed by a validated immunoassay to quantify SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration.\n",
      "\n",
      "TARGET SUMARY: This study will analyze the effects of SX-682 alone and in combination with M7824 by collecting and analyzing plasma and serum samples to measure drug concentration and detect the presence of M7824.\n",
      "\n",
      "Cosine similarity for summary 10: 0.82863855 \n",
      "\n",
      "Rouge scores for summary 10: {'rouge-1': {'r': 0.5, 'p': 0.5416666666666666, 'f': 0.5199999950080001}, 'rouge-2': {'r': 0.1935483870967742, 'p': 0.2222222222222222, 'f': 0.20689654674791927}, 'rouge-l': {'r': 0.4230769230769231, 'p': 0.4583333333333333, 'f': 0.43999999500799997}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Load peft config for pre-trained checkpoint etc. \n",
    "flan_t5_base_config = PeftConfig.from_pretrained(os.environ[\"FINETUNED_FLAN_T5_BASE_ID\"])\n",
    "\n",
    "# load base LLM model and tokenizer\n",
    "flan_t5_base_model = AutoModelForSeq2SeqLM.from_pretrained(\n",
    "    flan_t5_base_config.base_model_name_or_path,  \n",
    "    load_in_8bit=True,  \n",
    "    device_map=\"auto\",\n",
    ")\n",
    "\n",
    "flan_t5_base_tokenizer = AutoTokenizer.from_pretrained(\n",
    "    flan_t5_base_config.base_model_name_or_path, \n",
    ")\n",
    "\n",
    "flan_t5_base_performance = run_on_test_data(\n",
    "    flan_t5_base_model, \n",
    "    flan_t5_base_tokenizer, \n",
    "    INFERENCE_DATASET_KEY, \n",
    "    task=\"text2text-generation\", \n",
    "    n_docs=N_INFERENCE_DOCS,\n",
    "    log_summary=LOG_SUMMARY,\n",
    "    log_metrics=LOG_METRICS,\n",
    "    summary_chain_kwargs={\"combine_prompt\": PROMPT},\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9d0f1c2f-5931-4456-8244-40c73a0e4d7e",
   "metadata": {},
   "source": [
    "## Evaluate LoRA Fine-tuned FLAN-T5-BASE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "cf398748-4ec4-4a6a-9276-c155b8cce0ba",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The model 'PeftModelForSeq2SeqLM' is not supported for text2text-generation. Supported models are ['BartForConditionalGeneration', 'BigBirdPegasusForConditionalGeneration', 'BlenderbotForConditionalGeneration', 'BlenderbotSmallForConditionalGeneration', 'EncoderDecoderModel', 'FSMTForConditionalGeneration', 'GPTSanJapaneseForConditionalGeneration', 'LEDForConditionalGeneration', 'LongT5ForConditionalGeneration', 'M2M100ForConditionalGeneration', 'MarianMTModel', 'MBartForConditionalGeneration', 'MT5ForConditionalGeneration', 'MvpForConditionalGeneration', 'NllbMoeForConditionalGeneration', 'PegasusForConditionalGeneration', 'PegasusXForConditionalGeneration', 'PLBartForConditionalGeneration', 'ProphetNetForConditionalGeneration', 'SwitchTransformersForConditionalGeneration', 'T5ForConditionalGeneration', 'UMT5ForConditionalGeneration', 'XLMProphetNetForConditionalGeneration'].\n",
      "Token indices sequence length is longer than the specified maximum sequence length for this model (751 > 512). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1398: page_content='NCT Number: NCT03049449\\nStudy Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT03049449\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: Background:' metadata={}\n",
      "\n",
      "GENERATED SUMARY: A study has been conducted to assess the effectiveness of T cells with a specific antigen receptor for treating lymphomas in different cities in the United States. The study has been completed, but the acronym for the study is unknown.\n",
      "\n",
      "TARGET SUMARY: A study was conducted to explore the use of T cells with a specific receptor for treating lymphomas. The study has been completed, but no additional details are available.\n",
      "\n",
      "Cosine similarity for summary 1: 0.88253045 \n",
      "\n",
      "Rouge scores for summary 1: {'rouge-1': {'r': 0.7142857142857143, 'p': 0.6451612903225806, 'f': 0.6779660967078427}, 'rouge-2': {'r': 0.5357142857142857, 'p': 0.40540540540540543, 'f': 0.4615384566343196}, 'rouge-l': {'r': 0.7142857142857143, 'p': 0.6451612903225806, 'f': 0.6779660967078427}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 2909: page_content='Interventions: DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis\\nPrimary Outcome Measures: Incidence of relapsed leukemia, Incidence of relapsed leukemia defined as \\\\> 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have \\\\< 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease., Up to 18 months\\nSecondary Outcome Measures: Incidence of acute GVHD grades II-IV and III-IV, Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: This study will assess the relapsed leukemia and the occurrence of acute GVHD grades II-IV and III-IV in patients receiving Ibrutinib and laboratory biomarker analysis. The study will last 18 months and will include medical centers and cancer clinics in Texas and Utah.\n",
      "\n",
      "TARGET SUMARY: This study assesses the effectiveness of Ibrutinib in preventing relapsed leukemia after allogeneic hematopoietic cell transplantation. The primary outcome measure is the occurrence of relapsed leukemia, while secondary measures include the incidence of acute graft-versus-host disease.\n",
      "\n",
      "Cosine similarity for summary 2: 0.59234613 \n",
      "\n",
      "Rouge scores for summary 2: {'rouge-1': {'r': 0.3870967741935484, 'p': 0.36363636363636365, 'f': 0.3749999950048829}, 'rouge-2': {'r': 0.14285714285714285, 'p': 0.12195121951219512, 'f': 0.13157894239958468}, 'rouge-l': {'r': 0.3225806451612903, 'p': 0.30303030303030304, 'f': 0.31249999500488285}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 4698: page_content='54476, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical and cancer centers in different cities in the United States, including Lubbock, Texas; Marshfield, Menomonee Falls, Milwaukee, and Ogden in Wisconsin; and Oshkosh and Racine in Wyoming.\n",
      "\n",
      "TARGET SUMARY: This summary provides a list of medical centers in various cities in the United States, including Wisconsin Rapids, Wisconsin, and several cities in Wyoming. The medical centers mentioned include cancer centers and general medical facilities.\n",
      "\n",
      "Cosine similarity for summary 3: 0.7575477 \n",
      "\n",
      "Rouge scores for summary 3: {'rouge-1': {'r': 0.6296296296296297, 'p': 0.6071428571428571, 'f': 0.6181818131834711}, 'rouge-2': {'r': 0.40625, 'p': 0.3939393939393939, 'f': 0.3999999950011835}, 'rouge-l': {'r': 0.6296296296296297, 'p': 0.6071428571428571, 'f': 0.6181818131834711}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1949: page_content=\"Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87106, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, 87109, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, 88011, United States|Women's Cancer Care Associates LLC, Albany, New York, 12208, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|State University of New York Downstate Medical Center, Brooklyn, New York, 11203, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, 11215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|New York Hospital Medical Center of Queens, Fresh Meadows, New York, 11365, United States|Memorial Sloan Kettering\" metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical and cancer centers in Texas and New Mexico, including their addresses and zip codes.\n",
      "\n",
      "TARGET SUMARY: The summary provides a list of cancer centers and medical facilities in different US cities, such as New Jersey, New Mexico, and New York.\n",
      "\n",
      "Cosine similarity for summary 4: 0.7511077 \n",
      "\n",
      "Rouge scores for summary 4: {'rouge-1': {'r': 0.6190476190476191, 'p': 0.6842105263157895, 'f': 0.6499999950125002}, 'rouge-2': {'r': 0.34782608695652173, 'p': 0.4, 'f': 0.37209301828015146}, 'rouge-l': {'r': 0.5714285714285714, 'p': 0.631578947368421, 'f': 0.5999999950125001}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1354: page_content='Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\\nStudy Results: NO\\nConditions: Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia\\nInterventions: DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Etoposide\\nPrimary Outcome Measures: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors, 30 Days post treatment initiation' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The study is examining the effectiveness and safety of Carfilzomib, a combination treatment for multiple myeloma and solid tumors in pediatric patients. It has not yet generated any results.\n",
      "\n",
      "TARGET SUMARY: This research is studying the use of Carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors. The goal is to determine the maximum tolerated dose and any toxicities associated with this treatment. The primary focus is on assessing the safety and tolerability of the combination therapy.\n",
      "\n",
      "Cosine similarity for summary 5: 0.7342441 \n",
      "\n",
      "Rouge scores for summary 5: {'rouge-1': {'r': 0.358974358974359, 'p': 0.5, 'f': 0.4179104428959679}, 'rouge-2': {'r': 0.07692307692307693, 'p': 0.14285714285714285, 'f': 0.09999999545000023}, 'rouge-l': {'r': 0.28205128205128205, 'p': 0.39285714285714285, 'f': 0.3283582040899978}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3405: page_content='Other Outcome Measures: unknown\\nSponsor: Emory University\\nCollaborators: Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny|National Cancer Institute (NCI)|National Institutes of Health (NIH)\\nSex: ALL\\nAge: ADULT, OLDER_ADULT\\nPhases: PHASE1\\nEnrollment: 23\\nFunder Type: OTHER\\nStudy Type: INTERVENTIONAL\\nStudy Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\nOther IDs: IRB00104234|NCI-2018-01217|Winship4398-18|P30CA138292\\nStart Date: 2018-10-24\\nPrimary Completion Date: 2024-05-05\\nCompletion Date: 2024-05-05\\nFirst Posted: 2018-07-30\\nResults First Posted: unknown\\nLast Update Posted: 2023-05-31\\nLocations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States\\nStudy Documents: Informed Consent Form' metadata={}\n",
      "\n",
      "GENERATED SUMARY: This study, sponsored by Emory University and in collaboration with Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), and the National Institutes of Health (NIH), is evaluating an intervention for adult and older adult participants. The study is in Phase 1 and has enrolled 23 participants. It is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The study is expected to be completed on May 5, 2024. The study is being conducted at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah.\n",
      "\n",
      "TARGET SUMARY: This study, sponsored by Emory University and in collaboration with other organizations, is evaluating an intervention for adult and older adult patients with an unknown outcome measure. It is in Phase 1 and has enrolled 23 participants. The study is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The primary purpose is treatment. The study began on October 24, 2018, and is expected to be completed on May 5, 2024. The study is taking place at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah. The study includes an informed consent form.\n",
      "\n",
      "Cosine similarity for summary 6: 0.8921361 \n",
      "\n",
      "Rouge scores for summary 6: {'rouge-1': {'r': 0.7466666666666667, 'p': 0.7567567567567568, 'f': 0.7516778473492185}, 'rouge-2': {'r': 0.7142857142857143, 'p': 0.7211538461538461, 'f': 0.7177033442824112}, 'rouge-l': {'r': 0.7466666666666667, 'p': 0.7567567567567568, 'f': 0.7516778473492185}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1955: page_content='57701, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, 78745, United States|Texas Oncology Bedford, Bedford, Texas, 76022, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann Texas Medical Center, Houston, Texas, 77030, United States|West Texas Cancer Center, Odessa, Texas, 79761, United States|Houston Methodist' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical and cancer clinics in Texas and Utah.\n",
      "\n",
      "TARGET SUMARY: The list provides cancer treatment centers and hospitals in different cities in Texas, USA.\n",
      "\n",
      "Cosine similarity for summary 7: 0.7628169 \n",
      "\n",
      "Rouge scores for summary 7: {'rouge-1': {'r': 0.46153846153846156, 'p': 0.46153846153846156, 'f': 0.4615384565384616}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.3076923076923077, 'p': 0.3076923076923077, 'f': 0.3076923026923078}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3655: page_content='* Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.\\n* Partial response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: The summary provides a list of medical and cancer clinics in Texas and Utah. It mentions a partial response when all target lesions disappear, while a partial response when there is a 30% decrease in size of target lesions.\n",
      "\n",
      "TARGET SUMARY: A complete response in cancer treatment refers to the disappearance of all target lesions, decrease in lymph node size, disappearance of non-target lesions, and return of tumor marker levels to normal. A partial response is when there is at least a 30% decrease in the size of target lesions.\n",
      "\n",
      "Cosine similarity for summary 8: 0.7364237 \n",
      "\n",
      "Rouge scores for summary 8: {'rouge-1': {'r': 0.45714285714285713, 'p': 0.5714285714285714, 'f': 0.5079365029982364}, 'rouge-2': {'r': 0.21739130434782608, 'p': 0.29411764705882354, 'f': 0.24999999511250007}, 'rouge-l': {'r': 0.42857142857142855, 'p': 0.5357142857142857, 'f': 0.4761904712522046}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1636: page_content='NCT Number: NCT02785939\\nStudy Title: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT02785939\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.\\nStudy Results: YES\\nConditions: CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7' metadata={}\n",
      "\n",
      "GENERATED SUMARY: A phase II/III trial found that palbociclib may be effective in treating recurrent stage IV squamous cell lung cancer that has relapsed after previous treatment. It may slow cell cycle progression and shrink tumors. The study has been completed and the results are available.\n",
      "\n",
      "TARGET SUMARY: The study evaluated the effectiveness of palbociclib in treating patients with recurrent stage IV squamous cell lung cancer. Positive results were found, suggesting that palbociclib may slow down cell cycle progression and shrink tumors. The study focused on patients with cell cycle gene alterations.\n",
      "\n",
      "Cosine similarity for summary 9: 0.9337792 \n",
      "\n",
      "Rouge scores for summary 9: {'rouge-1': {'r': 0.6111111111111112, 'p': 0.5641025641025641, 'f': 0.5866666616746667}, 'rouge-2': {'r': 0.425, 'p': 0.3953488372093023, 'f': 0.40963854922339965}, 'rouge-l': {'r': 0.5833333333333334, 'p': 0.5384615384615384, 'f': 0.559999995008}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 330: page_content='10 months|Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)|Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)' metadata={}\n",
      "\n",
      "GENERATED SUMARY: This study will analyze the effects of SX-682 on plasma and serum samples before and after injection in different cities in the United States. The results will be analyzed using validated immunoassays.\n",
      "\n",
      "TARGET SUMARY: This study will analyze the effects of SX-682 alone and in combination with M7824 by collecting and analyzing plasma and serum samples to measure drug concentration and detect the presence of M7824.\n",
      "\n",
      "Cosine similarity for summary 10: 0.81626683 \n",
      "\n",
      "Rouge scores for summary 10: {'rouge-1': {'r': 0.5, 'p': 0.4642857142857143, 'f': 0.4814814764883402}, 'rouge-2': {'r': 0.3225806451612903, 'p': 0.3225806451612903, 'f': 0.3225806401612904}, 'rouge-l': {'r': 0.46153846153846156, 'p': 0.42857142857142855, 'f': 0.4444444394513032}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Load peft flan-t5-base\n",
    "flan_t5_base_model = PeftModel.from_pretrained(\n",
    "    flan_t5_base_model, \n",
    "    os.environ[\"FINETUNED_FLAN_T5_BASE_ID\"],\n",
    "    device_map=\"auto\"\n",
    ")\n",
    "flan_t5_base_tokenizer = AutoTokenizer.from_pretrained(\n",
    "    flan_t5_base_config.base_model_name_or_path, \n",
    "    max_length=os.environ[\"MAX_TOKENS\"],\n",
    ")\n",
    "\n",
    "lora_flan_t5_base_performance = run_on_test_data(\n",
    "    flan_t5_base_model, \n",
    "    flan_t5_base_tokenizer, \n",
    "    INFERENCE_DATASET_KEY, \n",
    "    task=\"text2text-generation\", \n",
    "    n_docs=N_INFERENCE_DOCS,\n",
    "    log_summary=LOG_SUMMARY,\n",
    "    log_metrics=LOG_METRICS,\n",
    "    summary_chain_kwargs={\"combine_prompt\": PROMPT},\n",
    ")\n",
    "\n",
    "if DELETE_LLM_AFTER_USE:\n",
    "    #model.to(torch.device(\"cpu\"))\n",
    "    del flan_t5_base_model, flan_t5_base_tokenizer\n",
    "    gc.collect()\n",
    "    torch.cuda.empty_cache()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "eded265e-2f71-4822-a48c-690d6ebc12e1",
   "metadata": {},
   "source": [
    "## Evaluate Base Pretrained Alpaca Native"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "3f24e94b-56da-46de-8295-45df2d86ca4b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "676a87f986214925a5f39fc01d869738",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/3 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "You are using the legacy behaviour of the <class 'transformers.models.llama.tokenization_llama.LlamaTokenizer'>. This means that tokens that come after special tokens will not be properly handled. We recommend you to read the related pull request available at https://github.com/huggingface/transformers/pull/24565\n",
      "Token indices sequence length is longer than the specified maximum sequence length for this model (887 > 512). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1398: page_content='NCT Number: NCT03049449\\nStudy Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT03049449\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: Background:' metadata={}\n",
      "\n",
      "GENERATED SUMARY:  This study is a Phase I clinical trial evaluating the safety and efficacy of T cells expressing a fully-human anti-CD30 chimeric antigen receptor (CAR) in patients with CD30-expressing lymphoma. The study will assess response rate, duration of response, and safety.\n",
      "\n",
      "TARGET SUMARY: A study was conducted to explore the use of T cells with a specific receptor for treating lymphomas. The study has been completed, but no additional details are available.\n",
      "\n",
      "Cosine similarity for summary 1: 0.7231908 \n",
      "\n",
      "Rouge scores for summary 1: {'rouge-1': {'r': 0.32142857142857145, 'p': 0.2571428571428571, 'f': 0.2857142807760142}, 'rouge-2': {'r': 0.10714285714285714, 'p': 0.07692307692307693, 'f': 0.08955223394074431}, 'rouge-l': {'r': 0.2857142857142857, 'p': 0.22857142857142856, 'f': 0.25396824902998244}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 2909: page_content='Interventions: DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis\\nPrimary Outcome Measures: Incidence of relapsed leukemia, Incidence of relapsed leukemia defined as \\\\> 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have \\\\< 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease., Up to 18 months\\nSecondary Outcome Measures: Incidence of acute GVHD grades II-IV and III-IV, Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study will compare the efficacy and safety of ibrutinib to laboratory biomarker analysis in participants with relapsed leukemia. The primary outcome measure is the rate of relapse, defined as more than 5% leukemic blasts present in either bone marrow or peripheral blood. Secondary outcomes include rates of acute GVHD grades II-IV and III-IV.\n",
      "\n",
      "TARGET SUMARY: This study assesses the effectiveness of Ibrutinib in preventing relapsed leukemia after allogeneic hematopoietic cell transplantation. The primary outcome measure is the occurrence of relapsed leukemia, while secondary measures include the incidence of acute graft-versus-host disease.\n",
      "\n",
      "Cosine similarity for summary 2: 0.84212554 \n",
      "\n",
      "Rouge scores for summary 2: {'rouge-1': {'r': 0.45161290322580644, 'p': 0.2857142857142857, 'f': 0.3499999952531251}, 'rouge-2': {'r': 0.22857142857142856, 'p': 0.1509433962264151, 'f': 0.18181817702737615}, 'rouge-l': {'r': 0.45161290322580644, 'p': 0.2857142857142857, 'f': 0.3499999952531251}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 4698: page_content='54476, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "The Aspirus UW Cancer Center in Wisconsin Rapids, Wisconsin, offers comprehensive cancer care services, as does the Marshfield Clinic - Wisconsin Rapids Center and the Cheyenne Regional Medical Center-West, both located in Wyoming. Billings Clinic-Cody and Welch Cancer Center, also located in Wyoming, specialize in cancer treatments and care.\n",
      "\n",
      "TARGET SUMARY: This summary provides a list of medical centers in various cities in the United States, including Wisconsin Rapids, Wisconsin, and several cities in Wyoming. The medical centers mentioned include cancer centers and general medical facilities.\n",
      "\n",
      "Cosine similarity for summary 3: 0.64600277 \n",
      "\n",
      "Rouge scores for summary 3: {'rouge-1': {'r': 0.3333333333333333, 'p': 0.24324324324324326, 'f': 0.2812499951220704}, 'rouge-2': {'r': 0.09375, 'p': 0.06382978723404255, 'f': 0.07594936226886749}, 'rouge-l': {'r': 0.2962962962962963, 'p': 0.21621621621621623, 'f': 0.24999999512207038}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1949: page_content=\"Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87106, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, 87109, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, 88011, United States|Women's Cancer Care Associates LLC, Albany, New York, 12208, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|State University of New York Downstate Medical Center, Brooklyn, New York, 11203, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, 11215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|New York Hospital Medical Center of Queens, Fresh Meadows, New York, 11365, United States|Memorial Sloan Kettering\" metadata={}\n",
      "\n",
      "GENERATED SUMARY:  There are several cancer centers located in various states in the US.\n",
      "\n",
      "TARGET SUMARY: The summary provides a list of cancer centers and medical facilities in different US cities, such as New Jersey, New Mexico, and New York.\n",
      "\n",
      "Cosine similarity for summary 4: 0.7722539 \n",
      "\n",
      "Rouge scores for summary 4: {'rouge-1': {'r': 0.19047619047619047, 'p': 0.36363636363636365, 'f': 0.2499999954882813}, 'rouge-2': {'r': 0.043478260869565216, 'p': 0.09090909090909091, 'f': 0.0588235250346024}, 'rouge-l': {'r': 0.19047619047619047, 'p': 0.36363636363636365, 'f': 0.2499999954882813}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1354: page_content='Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\\nStudy Results: NO\\nConditions: Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia\\nInterventions: DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Etoposide\\nPrimary Outcome Measures: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors, 30 Days post treatment initiation' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study will evaluate the safety and efficacy of carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\n",
      "\n",
      "TARGET SUMARY: This research is studying the use of Carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors. The goal is to determine the maximum tolerated dose and any toxicities associated with this treatment. The primary focus is on assessing the safety and tolerability of the combination therapy.\n",
      "\n",
      "Cosine similarity for summary 5: 0.95855296 \n",
      "\n",
      "Rouge scores for summary 5: {'rouge-1': {'r': 0.41025641025641024, 'p': 0.7619047619047619, 'f': 0.5333333287833334}, 'rouge-2': {'r': 0.3076923076923077, 'p': 0.6666666666666666, 'f': 0.4210526272576177}, 'rouge-l': {'r': 0.41025641025641024, 'p': 0.7619047619047619, 'f': 0.5333333287833334}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3405: page_content='Other Outcome Measures: unknown\\nSponsor: Emory University\\nCollaborators: Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny|National Cancer Institute (NCI)|National Institutes of Health (NIH)\\nSex: ALL\\nAge: ADULT, OLDER_ADULT\\nPhases: PHASE1\\nEnrollment: 23\\nFunder Type: OTHER\\nStudy Type: INTERVENTIONAL\\nStudy Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\nOther IDs: IRB00104234|NCI-2018-01217|Winship4398-18|P30CA138292\\nStart Date: 2018-10-24\\nPrimary Completion Date: 2024-05-05\\nCompletion Date: 2024-05-05\\nFirst Posted: 2018-07-30\\nResults First Posted: unknown\\nLast Update Posted: 2023-05-31\\nLocations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States\\nStudy Documents: Informed Consent Form' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This clinical trial is studying a new treatment for adults with acute lymphoblastic leukemia. Participants will be randomly assigned to receive either the experimental drug or a placebo. The primary outcome measure is overall survival, and other measures include progression-free survival, response rate, and adverse events. This study is being conducted at multiple locations in the US and is expected to be completed in May 2024.\n",
      "\n",
      "TARGET SUMARY: This study, sponsored by Emory University and in collaboration with other organizations, is evaluating an intervention for adult and older adult patients with an unknown outcome measure. It is in Phase 1 and has enrolled 23 participants. The study is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The primary purpose is treatment. The study began on October 24, 2018, and is expected to be completed on May 5, 2024. The study is taking place at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah. The study includes an informed consent form.\n",
      "\n",
      "Cosine similarity for summary 6: 0.4969241 \n",
      "\n",
      "Rouge scores for summary 6: {'rouge-1': {'r': 0.28, 'p': 0.3888888888888889, 'f': 0.3255813904813413}, 'rouge-2': {'r': 0.0761904761904762, 'p': 0.12307692307692308, 'f': 0.09411764233564039}, 'rouge-l': {'r': 0.25333333333333335, 'p': 0.35185185185185186, 'f': 0.29457363854335683}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1955: page_content='57701, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, 78745, United States|Texas Oncology Bedford, Bedford, Texas, 76022, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann Texas Medical Center, Houston, Texas, 77030, United States|West Texas Cancer Center, Odessa, Texas, 79761, United States|Houston Methodist' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This list includes cancer centers in the United States that specialize in treating various types of cancer, with experienced oncologists and other medical professionals.\n",
      "\n",
      "TARGET SUMARY: The list provides cancer treatment centers and hospitals in different cities in Texas, USA.\n",
      "\n",
      "Cosine similarity for summary 7: 0.66994375 \n",
      "\n",
      "Rouge scores for summary 7: {'rouge-1': {'r': 0.38461538461538464, 'p': 0.21739130434782608, 'f': 0.27777777316358027}, 'rouge-2': {'r': 0.0, 'p': 0.0, 'f': 0.0}, 'rouge-l': {'r': 0.3076923076923077, 'p': 0.17391304347826086, 'f': 0.22222221760802477}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3655: page_content='* Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.\\n* Partial response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "CR (complete response) and PR (partial response) are desired outcomes for this treatment, as evidenced by a disappearance of all target lesions and/or a reduction in pathological lymph nodes to <10mm.\n",
      "\n",
      "TARGET SUMARY: A complete response in cancer treatment refers to the disappearance of all target lesions, decrease in lymph node size, disappearance of non-target lesions, and return of tumor marker levels to normal. A partial response is when there is at least a 30% decrease in the size of target lesions.\n",
      "\n",
      "Cosine similarity for summary 8: 0.67822564 \n",
      "\n",
      "Rouge scores for summary 8: {'rouge-1': {'r': 0.2857142857142857, 'p': 0.3448275862068966, 'f': 0.3124999950439454}, 'rouge-2': {'r': 0.08695652173913043, 'p': 0.13333333333333333, 'f': 0.10526315311634371}, 'rouge-l': {'r': 0.2571428571428571, 'p': 0.3103448275862069, 'f': 0.2812499950439454}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1636: page_content='NCT Number: NCT02785939\\nStudy Title: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT02785939\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.\\nStudy Results: YES\\nConditions: CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7' metadata={}\n",
      "\n",
      "GENERATED SUMARY:  This study found that palbociclib is effective in slowing down the growth of tumors in patients with recurrent stage IV squamous cell lung cancer who have cell cycle gene alterations.\n",
      "\n",
      "TARGET SUMARY: The study evaluated the effectiveness of palbociclib in treating patients with recurrent stage IV squamous cell lung cancer. Positive results were found, suggesting that palbociclib may slow down cell cycle progression and shrink tumors. The study focused on patients with cell cycle gene alterations.\n",
      "\n",
      "Cosine similarity for summary 9: 0.96023446 \n",
      "\n",
      "Rouge scores for summary 9: {'rouge-1': {'r': 0.5555555555555556, 'p': 0.7142857142857143, 'f': 0.6249999950781252}, 'rouge-2': {'r': 0.3, 'p': 0.41379310344827586, 'f': 0.34782608208359594}, 'rouge-l': {'r': 0.5277777777777778, 'p': 0.6785714285714286, 'f': 0.593749995078125}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 330: page_content='10 months|Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)|Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study will collect samples from participants taking SX-682 alone or in combination with another drug for 10 months to measure its pharmacokinetics and pharmacodynamics.\n",
      "\n",
      "TARGET SUMARY: This study will analyze the effects of SX-682 alone and in combination with M7824 by collecting and analyzing plasma and serum samples to measure drug concentration and detect the presence of M7824.\n",
      "\n",
      "Cosine similarity for summary 10: 0.80101794 \n",
      "\n",
      "Rouge scores for summary 10: {'rouge-1': {'r': 0.5, 'p': 0.52, 'f': 0.5098039165705499}, 'rouge-2': {'r': 0.1935483870967742, 'p': 0.25, 'f': 0.21818181326281003}, 'rouge-l': {'r': 0.4230769230769231, 'p': 0.44, 'f': 0.4313725440215302}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "alpaca_config = AutoConfig.from_pretrained(os.environ[\"ALPACA_LLM\"])\n",
    "\n",
    "alpaca_model = LlamaForCausalLM.from_pretrained(\n",
    "    os.environ[\"ALPACA_LLM\"],\n",
    "    load_in_8bit=True,\n",
    "    device_map=\"auto\",\n",
    ")\n",
    "\n",
    "alpaca_tokenizer = LlamaTokenizer.from_pretrained(\n",
    "    os.environ[\"ALPACA_LLM\"], \n",
    "    max_length=alpaca_config.max_sequence_length,\n",
    ")\n",
    "\n",
    "alpaca_native_performance = run_on_test_data(\n",
    "    alpaca_model, \n",
    "    alpaca_tokenizer, \n",
    "    INFERENCE_DATASET_KEY, \n",
    "    task=\"text-generation\", \n",
    "    n_docs=N_INFERENCE_DOCS,\n",
    "    log_summary=LOG_SUMMARY,\n",
    "    log_metrics=LOG_METRICS,\n",
    "    summary_chain_kwargs={\"combine_prompt\": PROMPT},\n",
    ")\n",
    "\n",
    "if DELETE_LLM_AFTER_USE:\n",
    "    #model.to(torch.device(\"cpu\"))\n",
    "    del alpaca_model, alpaca_tokenizer\n",
    "    gc.collect()\n",
    "    torch.cuda.empty_cache()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8c248567-c864-4cad-9f56-40c41694e09c",
   "metadata": {},
   "source": [
    "## Evaluate Base Pretrained Vicuna 13b v1.3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "1b7df041-2cdb-46f8-81c6-ea8d2601e735",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c20722140f8d443e867030c0cd8b9d59",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/3 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DOCUMENT 1398: page_content='NCT Number: NCT03049449\\nStudy Title: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT03049449\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: Background:' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study is evaluating the safety and effectiveness of using T cells with a human anti-CD30 CAR for treating patients with CD30-expressing lymphomas. Results have not been released yet.\n",
      "\n",
      "TARGET SUMARY: A study was conducted to explore the use of T cells with a specific receptor for treating lymphomas. The study has been completed, but no additional details are available.\n",
      "\n",
      "Cosine similarity for summary 1: 0.68136454 \n",
      "\n",
      "Rouge scores for summary 1: {'rouge-1': {'r': 0.39285714285714285, 'p': 0.39285714285714285, 'f': 0.3928571378571429}, 'rouge-2': {'r': 0.14285714285714285, 'p': 0.14285714285714285, 'f': 0.14285713785714302}, 'rouge-l': {'r': 0.39285714285714285, 'p': 0.39285714285714285, 'f': 0.3928571378571429}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 2909: page_content='Interventions: DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis\\nPrimary Outcome Measures: Incidence of relapsed leukemia, Incidence of relapsed leukemia defined as \\\\> 5% leukemic blasts detected in bone marrow or peripheral blood. Participants will also be considered to have relapsed leukemia if they receive any active treatment for progressive leukemia after allogeneic HCT, even if they have \\\\< 5% leukemic blasts. Withdrawal of immunosuppression alone is not considered an active treatment for progressive disease., Up to 18 months\\nSecondary Outcome Measures: Incidence of acute GVHD grades II-IV and III-IV, Incidence of acute GVHD grades II-IV and III-IV will be evaluated according following criteria.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study investigates the use of ibrutinib, a drug for treating cancer, in preventing the relapse of leukemia in patients who have undergone allogenic hematopoietic cell transplantation. The primary outcome measure is the incidence of relapsed leukemia, while secondary outcomes include the incidences of acute GVHD grades II-IV and III-IV. The study will run for up to 18 months.\n",
      "\n",
      "TARGET SUMARY: This study assesses the effectiveness of Ibrutinib in preventing relapsed leukemia after allogeneic hematopoietic cell transplantation. The primary outcome measure is the occurrence of relapsed leukemia, while secondary measures include the incidence of acute graft-versus-host disease.\n",
      "\n",
      "Cosine similarity for summary 2: 0.9653967 \n",
      "\n",
      "Rouge scores for summary 2: {'rouge-1': {'r': 0.7096774193548387, 'p': 0.4489795918367347, 'f': 0.549999995253125}, 'rouge-2': {'r': 0.5142857142857142, 'p': 0.3103448275862069, 'f': 0.38709676949936417}, 'rouge-l': {'r': 0.6774193548387096, 'p': 0.42857142857142855, 'f': 0.524999995253125}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 4698: page_content='54476, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, 82001, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This text lists five medical facilities located in different cities across the United States.\n",
      "\n",
      "TARGET SUMARY: This summary provides a list of medical centers in various cities in the United States, including Wisconsin Rapids, Wisconsin, and several cities in Wyoming. The medical centers mentioned include cancer centers and general medical facilities.\n",
      "\n",
      "Cosine similarity for summary 3: 0.6525992 \n",
      "\n",
      "Rouge scores for summary 3: {'rouge-1': {'r': 0.25925925925925924, 'p': 0.5, 'f': 0.3414634101368233}, 'rouge-2': {'r': 0.0625, 'p': 0.15384615384615385, 'f': 0.0888888847802471}, 'rouge-l': {'r': 0.25925925925925924, 'p': 0.5, 'f': 0.3414634101368233}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1949: page_content=\"Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, 08043, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, 87106, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, 87109, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, 88011, United States|Women's Cancer Care Associates LLC, Albany, New York, 12208, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, 10461, United States|State University of New York Downstate Medical Center, Brooklyn, New York, 11203, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, 11215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|New York Hospital Medical Center of Queens, Fresh Meadows, New York, 11365, United States|Memorial Sloan Kettering\" metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "The text lists several cancer treatment centers and hospitals in different states across the US.\n",
      "\n",
      "TARGET SUMARY: The summary provides a list of cancer centers and medical facilities in different US cities, such as New Jersey, New Mexico, and New York.\n",
      "\n",
      "Cosine similarity for summary 4: 0.78591394 \n",
      "\n",
      "Rouge scores for summary 4: {'rouge-1': {'r': 0.3333333333333333, 'p': 0.4666666666666667, 'f': 0.3888888840277778}, 'rouge-2': {'r': 0.08695652173913043, 'p': 0.14285714285714285, 'f': 0.1081081034039447}, 'rouge-l': {'r': 0.3333333333333333, 'p': 0.4666666666666667, 'f': 0.3888888840277778}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1354: page_content='Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.\\nStudy Results: NO\\nConditions: Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia\\nInterventions: DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Etoposide\\nPrimary Outcome Measures: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors, 30 Days post treatment initiation' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study examines the use of Carfilzomib, an FDA-approved drug for treating adults with multiple myeloma, in combination with Cyclophosphamide and Etoposide for pediatric patients with relapsed/refractory leukemia or solid tumors. The aim is to determine the dosage limiting toxicity and maximum tolerated dose of the drug combination within 30 days of treatment initiation.\n",
      "\n",
      "TARGET SUMARY: This research is studying the use of Carfilzomib in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors. The goal is to determine the maximum tolerated dose and any toxicities associated with this treatment. The primary focus is on assessing the safety and tolerability of the combination therapy.\n",
      "\n",
      "Cosine similarity for summary 5: 0.8935176 \n",
      "\n",
      "Rouge scores for summary 5: {'rouge-1': {'r': 0.5384615384615384, 'p': 0.4772727272727273, 'f': 0.506024091403687}, 'rouge-2': {'r': 0.28846153846153844, 'p': 0.2830188679245283, 'f': 0.28571428071473925}, 'rouge-l': {'r': 0.5384615384615384, 'p': 0.4772727272727273, 'f': 0.506024091403687}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3405: page_content='Other Outcome Measures: unknown\\nSponsor: Emory University\\nCollaborators: Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny|National Cancer Institute (NCI)|National Institutes of Health (NIH)\\nSex: ALL\\nAge: ADULT, OLDER_ADULT\\nPhases: PHASE1\\nEnrollment: 23\\nFunder Type: OTHER\\nStudy Type: INTERVENTIONAL\\nStudy Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\nOther IDs: IRB00104234|NCI-2018-01217|Winship4398-18|P30CA138292\\nStart Date: 2018-10-24\\nPrimary Completion Date: 2024-05-05\\nCompletion Date: 2024-05-05\\nFirst Posted: 2018-07-30\\nResults First Posted: unknown\\nLast Update Posted: 2023-05-31\\nLocations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States\\nStudy Documents: Informed Consent Form' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "\n",
      "Emory University is conducting a Phase 1 clinical trial to evaluate the safety and effectiveness of a combination therapy involving an immune checkpoint inhibitor and a cancer vaccine for treating advanced or metastatic solid tumors. The study is open to adult patients who have not responded to previous treatments, and enrollment is ongoing with a primary completion date of May 2024.\n",
      "\n",
      "TARGET SUMARY: This study, sponsored by Emory University and in collaboration with other organizations, is evaluating an intervention for adult and older adult patients with an unknown outcome measure. It is in Phase 1 and has enrolled 23 participants. The study is funded by an unspecified source and is an interventional study with a non-randomized allocation and parallel intervention model. The primary purpose is treatment. The study began on October 24, 2018, and is expected to be completed on May 5, 2024. The study is taking place at Emory University Hospital/Winship Cancer Institute in Atlanta, Georgia, and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah. The study includes an informed consent form.\n",
      "\n",
      "Cosine similarity for summary 6: 0.53257537 \n",
      "\n",
      "Rouge scores for summary 6: {'rouge-1': {'r': 0.25333333333333335, 'p': 0.37254901960784315, 'f': 0.3015872967687075}, 'rouge-2': {'r': 0.05714285714285714, 'p': 0.1, 'f': 0.07272726809917385}, 'rouge-l': {'r': 0.22666666666666666, 'p': 0.3333333333333333, 'f': 0.2698412650226758}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1955: page_content='57701, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, 78745, United States|Texas Oncology Bedford, Bedford, Texas, 76022, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann Texas Medical Center, Houston, Texas, 77030, United States|West Texas Cancer Center, Odessa, Texas, 79761, United States|Houston Methodist' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "\n",
      "The text lists multiple locations of Texas Oncology and other cancer treatment centers in Texas.\n",
      "\n",
      "TARGET SUMARY: The list provides cancer treatment centers and hospitals in different cities in Texas, USA.\n",
      "\n",
      "Cosine similarity for summary 7: 0.85346776 \n",
      "\n",
      "Rouge scores for summary 7: {'rouge-1': {'r': 0.46153846153846156, 'p': 0.42857142857142855, 'f': 0.4444444394513032}, 'rouge-2': {'r': 0.15384615384615385, 'p': 0.14285714285714285, 'f': 0.14814814315500704}, 'rouge-l': {'r': 0.38461538461538464, 'p': 0.35714285714285715, 'f': 0.3703703653772291}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 3655: page_content='* Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.\\n* Partial response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "Complete response (CR) occurs when all target lesions disappear, affected lymph nodes shrink to less than 10mm, and non-target lesions are eliminated along with normalized tumor marker levels. Partial response (PR) involves a 30% reduction in target lesion size and no new lesions.\n",
      "\n",
      "TARGET SUMARY: A complete response in cancer treatment refers to the disappearance of all target lesions, decrease in lymph node size, disappearance of non-target lesions, and return of tumor marker levels to normal. A partial response is when there is at least a 30% decrease in the size of target lesions.\n",
      "\n",
      "Cosine similarity for summary 8: 0.825178 \n",
      "\n",
      "Rouge scores for summary 8: {'rouge-1': {'r': 0.45714285714285713, 'p': 0.42105263157894735, 'f': 0.43835615939200606}, 'rouge-2': {'r': 0.10869565217391304, 'p': 0.11904761904761904, 'f': 0.11363635864669443}, 'rouge-l': {'r': 0.37142857142857144, 'p': 0.34210526315789475, 'f': 0.35616437857008826}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 1636: page_content='NCT Number: NCT02785939\\nStudy Title: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer\\nStudy URL: https://beta.clinicaltrials.gov/study/NCT02785939\\nAcronym: unknown\\nStudy Status: COMPLETED\\nBrief Summary: This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.\\nStudy Results: YES\\nConditions: CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "Palbociclib, a drug that blocks proteins involved in cell division, was found to be effective in treating squamous cell lung cancer that had returned after previous treatment in patients with specific genetic changes.\n",
      "\n",
      "TARGET SUMARY: The study evaluated the effectiveness of palbociclib in treating patients with recurrent stage IV squamous cell lung cancer. Positive results were found, suggesting that palbociclib may slow down cell cycle progression and shrink tumors. The study focused on patients with cell cycle gene alterations.\n",
      "\n",
      "Cosine similarity for summary 9: 0.84973776 \n",
      "\n",
      "Rouge scores for summary 9: {'rouge-1': {'r': 0.25, 'p': 0.3103448275862069, 'f': 0.2769230719810652}, 'rouge-2': {'r': 0.125, 'p': 0.15625, 'f': 0.13888888395061746}, 'rouge-l': {'r': 0.25, 'p': 0.3103448275862069, 'f': 0.2769230719810652}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n",
      "DOCUMENT 330: page_content='10 months|Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)|Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination, Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration., Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)' metadata={}\n",
      "\n",
      "GENERATED SUMARY: \n",
      "This study will examine the properties of SX-682, both alone and in combination with M7824, by measuring drug concentrations and their effects on the body over time.\n",
      "\n",
      "TARGET SUMARY: This study will analyze the effects of SX-682 alone and in combination with M7824 by collecting and analyzing plasma and serum samples to measure drug concentration and detect the presence of M7824.\n",
      "\n",
      "Cosine similarity for summary 10: 0.91918373 \n",
      "\n",
      "Rouge scores for summary 10: {'rouge-1': {'r': 0.5, 'p': 0.52, 'f': 0.5098039165705499}, 'rouge-2': {'r': 0.1935483870967742, 'p': 0.23076923076923078, 'f': 0.21052631082794718}, 'rouge-l': {'r': 0.46153846153846156, 'p': 0.48, 'f': 0.47058823029604}} \n",
      "\n",
      "------------------------------------------------------------------------------------------------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "vicuna_model = AutoModelForCausalLM.from_pretrained(\n",
    "    os.environ[\"VICUNA_LLM\"],\n",
    "    load_in_8bit=True,\n",
    "    device_map=\"auto\",\n",
    ")\n",
    "\n",
    "vicuna_tokenizer = AutoTokenizer.from_pretrained(\n",
    "    os.environ[\"VICUNA_LLM\"], \n",
    "    max_length=os.environ[\"MAX_TOKENS\"],\n",
    ")\n",
    "\n",
    "vicuna_13b_performance = run_on_test_data(\n",
    "    vicuna_model, \n",
    "    vicuna_tokenizer, \n",
    "    INFERENCE_DATASET_KEY, \n",
    "    task=\"text-generation\", \n",
    "    n_docs=N_INFERENCE_DOCS,\n",
    "    log_summary=LOG_SUMMARY,\n",
    "    log_metrics=LOG_METRICS,\n",
    "    summary_chain_kwargs={\"combine_prompt\": PROMPT},\n",
    ")\n",
    "\n",
    "if DELETE_LLM_AFTER_USE:\n",
    "    #model.to(torch.device(\"cpu\"))\n",
    "    del vicuna_model, vicuna_tokenizer\n",
    "    gc.collect()\n",
    "    torch.cuda.empty_cache()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "1fb94c09-37a3-45b1-b1a4-448d5fb8b4ef",
   "metadata": {},
   "outputs": [],
   "source": [
    "def compile_metrics(performance: Iterable[Dict[str, Any]], outer_key: Optional[str]=None) -> Dict[str, Iterable]:\n",
    "    performance_table_dict = dict()\n",
    "    performance_dict = dict()\n",
    "    join_keys = lambda inner_key : (outer_key, inner_key) if outer_key else inner_key\n",
    "    \n",
    "    for i, item in enumerate(performance):\n",
    "        similarity_score = item[\"semantic_similarity\"][0][0]\n",
    "        rouge_scores = item[\"rouge_scores\"][0]\n",
    "        if i == 0:\n",
    "            performance_dict[join_keys(\"similarity_score\")]=[similarity_score]\n",
    "        else:\n",
    "            performance_dict[join_keys(\"similarity_score\")].append(similarity_score)\n",
    "        for key in rouge_scores.keys():\n",
    "            if i == 0:\n",
    "                performance_dict = {\n",
    "                    **performance_dict, \n",
    "                    **{join_keys(f\"{key}_{k}\"):[v] for k, v in rouge_scores[key].items()}\n",
    "                }\n",
    "            else:\n",
    "                for k, v in rouge_scores[key].items():\n",
    "                    performance_dict[join_keys(f\"{key}_{k}\")].append(v)\n",
    "    return performance_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "4158c6ca-b4e0-4ec4-9ceb-346c85d9c35b",
   "metadata": {},
   "outputs": [],
   "source": [
    "performances = {\n",
    "    \"flan-t5-small\": flan_t5_small_performance,\n",
    "    \"lora-peft-flan-t5-small\": lora_flan_t5_small_performance,\n",
    "    \"flan-t5-base\": flan_t5_base_performance,\n",
    "    \"lora-peft-flan-t5-base\": lora_flan_t5_base_performance,\n",
    "    \"alpaca-7b-native\": alpaca_native_performance,\n",
    "    \"vicuna-13b-v1.3\": vicuna_13b_performance,\n",
    "}\n",
    "metrics_dict = dict()\n",
    "for key, performance_values in performances.items():\n",
    "    metrics_dict = {**metrics_dict, **compile_metrics(performance_values, outer_key=key)}\n",
    "    \n",
    "outer_cols = [k for k in performances.keys()]\n",
    "inner_cols = [k[1] for k in metrics_dict.keys() if k[0]==\"flan-t5-small\"]\n",
    "columns = pd.MultiIndex.from_product([outer_cols, inner_cols])\n",
    "metrics_df = pd.DataFrame(metrics_dict, columns=columns).round(2)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "780907f4-03b0-4f7e-a421-79690d3951d7",
   "metadata": {},
   "source": [
    "## Performance Comparison Table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f94c7f28-7c0d-447a-a12d-cf151927fc4c",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead tr th {\n",
       "        text-align: left;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th colspan=\"10\" halign=\"left\">flan-t5-small</th>\n",
       "      <th colspan=\"10\" halign=\"left\">lora-peft-flan-t5-small</th>\n",
       "      <th colspan=\"10\" halign=\"left\">flan-t5-base</th>\n",
       "      <th colspan=\"10\" halign=\"left\">lora-peft-flan-t5-base</th>\n",
       "      <th colspan=\"10\" halign=\"left\">alpaca-7b-native</th>\n",
       "      <th colspan=\"10\" halign=\"left\">vicuna-13b-v1.3</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.68</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.59</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.30</td>\n",
       "      <td>0.16</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.88</td>\n",
       "      <td>0.71</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.71</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.72</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.39</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.80</td>\n",
       "      <td>0.16</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.21</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.17</td>\n",
       "      <td>0.79</td>\n",
       "      <td>0.55</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.27</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.78</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.16</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.21</td>\n",
       "      <td>0.59</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.30</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.84</td>\n",
       "      <td>0.45</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.45</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.97</td>\n",
       "      <td>0.71</td>\n",
       "      <td>0.45</td>\n",
       "      <td>0.55</td>\n",
       "      <td>0.51</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.58</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.83</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.79</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.45</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.79</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.58</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.57</td>\n",
       "      <td>0.52</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.52</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.63</td>\n",
       "      <td>0.61</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.40</td>\n",
       "      <td>0.63</td>\n",
       "      <td>0.61</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.30</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.34</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.70</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.17</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.16</td>\n",
       "      <td>0.81</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.57</td>\n",
       "      <td>0.63</td>\n",
       "      <td>0.60</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.75</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.65</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.40</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.57</td>\n",
       "      <td>0.63</td>\n",
       "      <td>0.60</td>\n",
       "      <td>0.77</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.79</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.47</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.47</td>\n",
       "      <td>0.39</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.12</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.64</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.64</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.64</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.73</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.96</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.67</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.89</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.51</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.51</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>0.16</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.57</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.89</td>\n",
       "      <td>0.75</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.75</td>\n",
       "      <td>0.71</td>\n",
       "      <td>0.72</td>\n",
       "      <td>0.72</td>\n",
       "      <td>0.75</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.75</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.30</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.68</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.21</td>\n",
       "      <td>0.83</td>\n",
       "      <td>0.77</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.72</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.76</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.67</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.17</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.85</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.37</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>0.09</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.40</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.04</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.30</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.74</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.57</td>\n",
       "      <td>0.51</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.34</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.83</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.34</td>\n",
       "      <td>0.36</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>0.90</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.45</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.94</td>\n",
       "      <td>0.69</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.66</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.47</td>\n",
       "      <td>0.69</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.66</td>\n",
       "      <td>0.69</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.93</td>\n",
       "      <td>0.61</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.59</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.40</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.58</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.96</td>\n",
       "      <td>0.56</td>\n",
       "      <td>0.71</td>\n",
       "      <td>0.62</td>\n",
       "      <td>0.30</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.59</td>\n",
       "      <td>0.85</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.12</td>\n",
       "      <td>0.16</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.28</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>0.79</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.53</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.73</td>\n",
       "      <td>0.27</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.11</td>\n",
       "      <td>0.27</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.29</td>\n",
       "      <td>0.83</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.52</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.21</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.82</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.32</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.80</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.52</td>\n",
       "      <td>0.51</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.92</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.52</td>\n",
       "      <td>0.51</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.21</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.47</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     flan-t5-small                                                    \\\n",
       "  similarity_score rouge-1_r rouge-1_p rouge-1_f rouge-2_r rouge-2_p   \n",
       "0             0.68      0.18      0.20      0.19      0.04      0.04   \n",
       "1             0.80      0.16      0.29      0.21      0.03      0.06   \n",
       "2             0.58      0.33      0.29      0.31      0.09      0.08   \n",
       "3             0.70      0.24      0.17      0.20      0.09      0.05   \n",
       "4             0.12      0.13      0.38      0.19      0.00      0.00   \n",
       "5             0.16      0.01      0.12      0.02      0.00      0.00   \n",
       "6             0.68      0.38      0.19      0.26      0.00      0.00   \n",
       "7             0.09      0.03      0.14      0.05      0.00      0.00   \n",
       "8             0.90      0.39      0.45      0.42      0.22      0.29   \n",
       "9             0.79      0.35      0.53      0.42      0.19      0.35   \n",
       "\n",
       "                                          lora-peft-flan-t5-small            \\\n",
       "  rouge-2_f rouge-l_r rouge-l_p rouge-l_f        similarity_score rouge-1_r   \n",
       "0      0.04      0.18      0.20      0.19                    0.20      0.11   \n",
       "1      0.04      0.13      0.24      0.17                    0.79      0.55   \n",
       "2      0.08      0.26      0.23      0.24                    0.83      0.56   \n",
       "3      0.07      0.19      0.13      0.16                    0.81      0.62   \n",
       "4      0.00      0.10      0.31      0.15                    0.76      0.41   \n",
       "5      0.00      0.01      0.12      0.02                    0.57      0.23   \n",
       "6      0.00      0.31      0.15      0.21                    0.83      0.77   \n",
       "7      0.00      0.03      0.14      0.05                    0.28      0.14   \n",
       "8      0.25      0.33      0.39      0.36                    0.94      0.69   \n",
       "9      0.25      0.35      0.53      0.42                    0.73      0.27   \n",
       "\n",
       "                                                                         \\\n",
       "  rouge-1_p rouge-1_f rouge-2_r rouge-2_p rouge-2_f rouge-l_r rouge-l_p   \n",
       "0      0.19      0.14      0.00      0.00      0.00      0.07      0.12   \n",
       "1      0.42      0.48      0.31      0.23      0.27      0.48      0.38   \n",
       "2      0.79      0.65      0.28      0.45      0.35      0.56      0.79   \n",
       "3      0.68      0.65      0.39      0.43      0.41      0.57      0.63   \n",
       "4      0.64      0.50      0.19      0.38      0.26      0.41      0.64   \n",
       "5      0.50      0.31      0.09      0.24      0.13      0.23      0.50   \n",
       "6      0.53      0.62      0.23      0.15      0.18      0.62      0.42   \n",
       "7      0.31      0.20      0.00      0.00      0.00      0.09      0.19   \n",
       "8      0.62      0.66      0.50      0.43      0.47      0.69      0.62   \n",
       "9      0.32      0.29      0.10      0.13      0.11      0.27      0.32   \n",
       "\n",
       "                flan-t5-base                                          \\\n",
       "  rouge-l_f similarity_score rouge-1_r rouge-1_p rouge-1_f rouge-2_r   \n",
       "0      0.09             0.59      0.11      0.30      0.16      0.00   \n",
       "1      0.42             0.78      0.19      0.35      0.25      0.06   \n",
       "2      0.65             0.58      0.48      0.57      0.52      0.19   \n",
       "3      0.60             0.50      0.14      0.15      0.15      0.00   \n",
       "4      0.50             0.64      0.08      0.38      0.13      0.00   \n",
       "5      0.31             0.36      0.05      0.24      0.09      0.00   \n",
       "6      0.50             0.72      0.15      0.22      0.18      0.00   \n",
       "7      0.12             0.29      0.11      0.40      0.18      0.02   \n",
       "8      0.66             0.69      0.14      0.56      0.22      0.08   \n",
       "9      0.29             0.83      0.50      0.54      0.52      0.19   \n",
       "\n",
       "                                                    lora-peft-flan-t5-base  \\\n",
       "  rouge-2_p rouge-2_f rouge-l_r rouge-l_p rouge-l_f       similarity_score   \n",
       "0      0.00      0.00      0.07      0.20      0.11                   0.88   \n",
       "1      0.12      0.08      0.16      0.29      0.21                   0.59   \n",
       "2      0.22      0.20      0.44      0.52      0.48                   0.76   \n",
       "3      0.00      0.00      0.14      0.15      0.15                   0.75   \n",
       "4      0.00      0.00      0.08      0.38      0.13                   0.73   \n",
       "5      0.00      0.00      0.05      0.24      0.09                   0.89   \n",
       "6      0.00      0.00      0.15      0.22      0.18                   0.76   \n",
       "7      0.11      0.04      0.09      0.30      0.13                   0.74   \n",
       "8      0.38      0.12      0.14      0.56      0.22                   0.93   \n",
       "9      0.22      0.21      0.42      0.46      0.44                   0.82   \n",
       "\n",
       "                                                                         \\\n",
       "  rouge-1_r rouge-1_p rouge-1_f rouge-2_r rouge-2_p rouge-2_f rouge-l_r   \n",
       "0      0.71      0.65      0.68      0.54      0.41      0.46      0.71   \n",
       "1      0.39      0.36      0.37      0.14      0.12      0.13      0.32   \n",
       "2      0.63      0.61      0.62      0.41      0.39      0.40      0.63   \n",
       "3      0.62      0.68      0.65      0.35      0.40      0.37      0.57   \n",
       "4      0.36      0.50      0.42      0.08      0.14      0.10      0.28   \n",
       "5      0.75      0.76      0.75      0.71      0.72      0.72      0.75   \n",
       "6      0.46      0.46      0.46      0.00      0.00      0.00      0.31   \n",
       "7      0.46      0.57      0.51      0.22      0.29      0.25      0.43   \n",
       "8      0.61      0.56      0.59      0.42      0.40      0.41      0.58   \n",
       "9      0.50      0.46      0.48      0.32      0.32      0.32      0.46   \n",
       "\n",
       "                      alpaca-7b-native                                \\\n",
       "  rouge-l_p rouge-l_f similarity_score rouge-1_r rouge-1_p rouge-1_f   \n",
       "0      0.65      0.68             0.72      0.32      0.26      0.29   \n",
       "1      0.30      0.31             0.84      0.45      0.29      0.35   \n",
       "2      0.61      0.62             0.65      0.33      0.24      0.28   \n",
       "3      0.63      0.60             0.77      0.19      0.36      0.25   \n",
       "4      0.39      0.33             0.96      0.41      0.76      0.53   \n",
       "5      0.76      0.75             0.50      0.28      0.39      0.33   \n",
       "6      0.31      0.31             0.67      0.38      0.22      0.28   \n",
       "7      0.54      0.48             0.68      0.29      0.34      0.31   \n",
       "8      0.54      0.56             0.96      0.56      0.71      0.62   \n",
       "9      0.43      0.44             0.80      0.50      0.52      0.51   \n",
       "\n",
       "                                                               \\\n",
       "  rouge-2_r rouge-2_p rouge-2_f rouge-l_r rouge-l_p rouge-l_f   \n",
       "0      0.11      0.08      0.09      0.29      0.23      0.25   \n",
       "1      0.23      0.15      0.18      0.45      0.29      0.35   \n",
       "2      0.09      0.06      0.08      0.30      0.22      0.25   \n",
       "3      0.04      0.09      0.06      0.19      0.36      0.25   \n",
       "4      0.31      0.67      0.42      0.41      0.76      0.53   \n",
       "5      0.08      0.12      0.09      0.25      0.35      0.29   \n",
       "6      0.00      0.00      0.00      0.31      0.17      0.22   \n",
       "7      0.09      0.13      0.11      0.26      0.31      0.28   \n",
       "8      0.30      0.41      0.35      0.53      0.68      0.59   \n",
       "9      0.19      0.25      0.22      0.42      0.44      0.43   \n",
       "\n",
       "   vicuna-13b-v1.3                                                    \\\n",
       "  similarity_score rouge-1_r rouge-1_p rouge-1_f rouge-2_r rouge-2_p   \n",
       "0             0.68      0.39      0.39      0.39      0.14      0.14   \n",
       "1             0.97      0.71      0.45      0.55      0.51      0.31   \n",
       "2             0.65      0.26      0.50      0.34      0.06      0.15   \n",
       "3             0.79      0.33      0.47      0.39      0.09      0.14   \n",
       "4             0.89      0.54      0.48      0.51      0.29      0.28   \n",
       "5             0.53      0.25      0.37      0.30      0.06      0.10   \n",
       "6             0.85      0.46      0.43      0.44      0.15      0.14   \n",
       "7             0.83      0.46      0.42      0.44      0.11      0.12   \n",
       "8             0.85      0.25      0.31      0.28      0.12      0.16   \n",
       "9             0.92      0.50      0.52      0.51      0.19      0.23   \n",
       "\n",
       "                                           \n",
       "  rouge-2_f rouge-l_r rouge-l_p rouge-l_f  \n",
       "0      0.14      0.39      0.39      0.39  \n",
       "1      0.39      0.68      0.43      0.52  \n",
       "2      0.09      0.26      0.50      0.34  \n",
       "3      0.11      0.33      0.47      0.39  \n",
       "4      0.29      0.54      0.48      0.51  \n",
       "5      0.07      0.23      0.33      0.27  \n",
       "6      0.15      0.38      0.36      0.37  \n",
       "7      0.11      0.37      0.34      0.36  \n",
       "8      0.14      0.25      0.31      0.28  \n",
       "9      0.21      0.46      0.48      0.47  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.set_option('display.max_columns', None)\n",
    "metrics_df"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "da5c36b2-a5a3-49b2-b413-a4b5bd91b6e7",
   "metadata": {},
   "source": [
    "## Mean Performance Comparison Table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "7b796d18-d06e-421e-839f-c0fdf78af83e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead tr th {\n",
       "        text-align: left;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th colspan=\"10\" halign=\"left\">flan-t5-small</th>\n",
       "      <th colspan=\"10\" halign=\"left\">lora-peft-flan-t5-small</th>\n",
       "      <th colspan=\"10\" halign=\"left\">flan-t5-base</th>\n",
       "      <th colspan=\"10\" halign=\"left\">lora-peft-flan-t5-base</th>\n",
       "      <th colspan=\"10\" halign=\"left\">alpaca-7b-native</th>\n",
       "      <th colspan=\"10\" halign=\"left\">vicuna-13b-v1.3</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "      <th>similarity_score</th>\n",
       "      <th>rouge-1_r</th>\n",
       "      <th>rouge-1_p</th>\n",
       "      <th>rouge-1_f</th>\n",
       "      <th>rouge-2_r</th>\n",
       "      <th>rouge-2_p</th>\n",
       "      <th>rouge-2_f</th>\n",
       "      <th>rouge-l_r</th>\n",
       "      <th>rouge-l_p</th>\n",
       "      <th>rouge-l_f</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.55</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.276</td>\n",
       "      <td>0.227</td>\n",
       "      <td>0.066</td>\n",
       "      <td>0.087</td>\n",
       "      <td>0.073</td>\n",
       "      <td>0.189</td>\n",
       "      <td>0.244</td>\n",
       "      <td>0.197</td>\n",
       "      <td>0.674</td>\n",
       "      <td>0.435</td>\n",
       "      <td>0.5</td>\n",
       "      <td>0.45</td>\n",
       "      <td>0.209</td>\n",
       "      <td>0.244</td>\n",
       "      <td>0.218</td>\n",
       "      <td>0.399</td>\n",
       "      <td>0.461</td>\n",
       "      <td>0.414</td>\n",
       "      <td>0.598</td>\n",
       "      <td>0.195</td>\n",
       "      <td>0.371</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.054</td>\n",
       "      <td>0.105</td>\n",
       "      <td>0.065</td>\n",
       "      <td>0.174</td>\n",
       "      <td>0.332</td>\n",
       "      <td>0.214</td>\n",
       "      <td>0.785</td>\n",
       "      <td>0.549</td>\n",
       "      <td>0.561</td>\n",
       "      <td>0.553</td>\n",
       "      <td>0.319</td>\n",
       "      <td>0.319</td>\n",
       "      <td>0.316</td>\n",
       "      <td>0.504</td>\n",
       "      <td>0.516</td>\n",
       "      <td>0.508</td>\n",
       "      <td>0.755</td>\n",
       "      <td>0.371</td>\n",
       "      <td>0.409</td>\n",
       "      <td>0.375</td>\n",
       "      <td>0.144</td>\n",
       "      <td>0.196</td>\n",
       "      <td>0.16</td>\n",
       "      <td>0.341</td>\n",
       "      <td>0.381</td>\n",
       "      <td>0.344</td>\n",
       "      <td>0.796</td>\n",
       "      <td>0.415</td>\n",
       "      <td>0.434</td>\n",
       "      <td>0.415</td>\n",
       "      <td>0.172</td>\n",
       "      <td>0.177</td>\n",
       "      <td>0.17</td>\n",
       "      <td>0.389</td>\n",
       "      <td>0.409</td>\n",
       "      <td>0.39</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     flan-t5-small                                                    \\\n",
       "  similarity_score rouge-1_r rouge-1_p rouge-1_f rouge-2_r rouge-2_p   \n",
       "0             0.55      0.22     0.276     0.227     0.066     0.087   \n",
       "\n",
       "                                          lora-peft-flan-t5-small            \\\n",
       "  rouge-2_f rouge-l_r rouge-l_p rouge-l_f        similarity_score rouge-1_r   \n",
       "0     0.073     0.189     0.244     0.197                   0.674     0.435   \n",
       "\n",
       "                                                                         \\\n",
       "  rouge-1_p rouge-1_f rouge-2_r rouge-2_p rouge-2_f rouge-l_r rouge-l_p   \n",
       "0       0.5      0.45     0.209     0.244     0.218     0.399     0.461   \n",
       "\n",
       "                flan-t5-base                                          \\\n",
       "  rouge-l_f similarity_score rouge-1_r rouge-1_p rouge-1_f rouge-2_r   \n",
       "0     0.414            0.598     0.195     0.371      0.24     0.054   \n",
       "\n",
       "                                                    lora-peft-flan-t5-base  \\\n",
       "  rouge-2_p rouge-2_f rouge-l_r rouge-l_p rouge-l_f       similarity_score   \n",
       "0     0.105     0.065     0.174     0.332     0.214                  0.785   \n",
       "\n",
       "                                                                         \\\n",
       "  rouge-1_r rouge-1_p rouge-1_f rouge-2_r rouge-2_p rouge-2_f rouge-l_r   \n",
       "0     0.549     0.561     0.553     0.319     0.319     0.316     0.504   \n",
       "\n",
       "                      alpaca-7b-native                                \\\n",
       "  rouge-l_p rouge-l_f similarity_score rouge-1_r rouge-1_p rouge-1_f   \n",
       "0     0.516     0.508            0.755     0.371     0.409     0.375   \n",
       "\n",
       "                                                               \\\n",
       "  rouge-2_r rouge-2_p rouge-2_f rouge-l_r rouge-l_p rouge-l_f   \n",
       "0     0.144     0.196      0.16     0.341     0.381     0.344   \n",
       "\n",
       "   vicuna-13b-v1.3                                                    \\\n",
       "  similarity_score rouge-1_r rouge-1_p rouge-1_f rouge-2_r rouge-2_p   \n",
       "0            0.796     0.415     0.434     0.415     0.172     0.177   \n",
       "\n",
       "                                           \n",
       "  rouge-2_f rouge-l_r rouge-l_p rouge-l_f  \n",
       "0      0.17     0.389     0.409      0.39  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metrics_mean = metrics_df.mean(axis=0)\n",
    "mean_metrics_df = pd.DataFrame(metrics_mean.values.reshape(1, -1), columns=metrics_mean.index)\n",
    "mean_metrics_df"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
